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THE CANCER STEM CELLS AND HUMAN LIVER CANCER: 
identifications, expressions, and drug resistance 
 
 
Caecilia H.C. Sukowati 
Summary 
 
The advance information on molecular biology and medicine had suggested a new theory 
of the initiation of the cancer. Cancer is composed in a hierarchy of many types of cells with 
various degree of differentiation in which there is only a small proportion of cells can initiate 
and sustain the tumor growth. These cells are known as the cancer stem cells (CSCs). The 
CSCs still possess the whole capacity as the normal stem cells to self-renew, to differentiate 
into multiple types of cells and to proliferate extensively. In the liver cancer, the 
characteristics of the hepatic CSCs remain unclear. They might be resident hepatic stem cells 
or derived/migrated stem cells from bone marrow. Several molecular markers such as CD90, 
CD44, CD133, EpCAM, and so-called side populations with ABCG2 expression had been 
proposed. The ABCG2 expression is closely related with drug resistance in cancers.  
The general objective of this study is to better understand the heterogeneity of cancer 
stem cells in hepatic system. This general objective was specified into three interrelated 
projects: 1) to isolate and characterize the stem cells from different tissues parts of several 
human liver malignancies, mainly HCC and CC; 2) to assess the expression of several stem 
cells markers in clinical samples tissues; 3) to study the expression of a drug transporter 
ABCG2 in relation with cells differentiation and drug resistance. 
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We had isolated cells populations from distant pair of neoplastic and distal tissues of HCC 
and CC patients. These isolated cells co-expressed CD90 and CD44 but not hematopoietic 
stem cells markers CD34. Further analysis showed that they express mesenchymal surface 
markers and also pluripotency factors. This population had cells with cytokeratin expression 
and low albumin expression. When they were plated in low density, they cloned and formed 
fibroblastic-like colonies. These data suggested that these isolated cells populations contained 
mesencyhmal stem cells. Interestingly, when they were induced into insulin producing cells, 
they showed up-regulations of markers of pancreatic cells, indicating their potential to 
transdifferentiate to endodermal lineage. One line had capacity to differentiate into 
adipogenic lineage, demonstrated by the fat droplets accumulation in the cytoplasm and high 
expression of peroxisome proliferator-activated receptor gamma (PPARG). These results had 
provided the evidences that stem cells from cancerous tissues had capacity to trans-
differentiate into insulin producing cells and adipocytes. As expected, both stem cells from 
neoplastic and distal tissues both shared similar phenotypic markers. We assumed that the 
differences between them might be on different mechanisms of molecular pathways of those 
cells.  
From our study in clinical tissues samples, we found that the distribution of stem cells 
markers genes from liver malignancies tissues were highly variable. Interestingly, it showed 
that there was a tendency that the expressions of these genes were higher in the diseased 
tissues than in normal tissues and in the lesion than distal tissues. These results may imply 
that there was active proliferation of the stem cells in the cancer and may represent the 
tumorigenesis process from normal to disease tissues.  
Concerning the drug resistance issue, we found that the expression of ABCG2 in clinical 
samples was higher in neoplastic tissues compared to distal and young normal tissues. To 
support data in vivo, we employed several hepatic cell lines for data in vitro. We observed 
that ABCG2 was significantly highest in the most undifferentiated cell lines JHH-6. The 
Hoechst 33342 efflux assay demonstrated that this line also had the highest capacity to pump 
out the substrate from the cells. After exposure to doxorubicin, a common anti-neoplastic 
agent, all hepatic cell lines showed up-regulations of ABCG2, the highest up-regulations were 
detected in cell lines which had low basal ABCG2 expression.  
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All the data shown in this study has supported the presence of stem cells in liver cancer. 
This summary might be only small contributions in the knowledge of hepatocarcinogenesis 
and cancerogenesis in general. However, more data in the characterizations of both normal 
SCs and CSCs are important for better understanding their mechanisms in cancer initiation, 
maintenance, and treatment. This should be achieved by several steps. First, it is important to 
know how the CSCs initiate the cancer. Second, the identification of specific markers for these 
cells for a specific targeting of CSCs while sparing normal SCs, might be some structural 
protein markers or specifically different mechanisms in cell pathways. Third, it is important 
to understand the better handling of drug resistance problem in cancer. 
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CELLULE STAMINALI TUMORALI E TUMORE EPATICO 
PRIMITIVO UMANO: 
identificazione, espressione e chemioresistenza 
 
 
Caecilia H.C. Sukowati 
 
Riassunto 
Le scoperte più recenti in campo biomedico hanno proposto una nuova teoria sull’'inizio 
del cancro.  Secondo queste ipotesi il tumore è composto da una popolazione eterogenea  di 
cellule a diverso grado di differenziamento in cui  solo una piccola percentuale è  in grado di 
avviare e sostenere la crescita del tumore. Queste cellule sono conosciute con il nome di  
cellule staminali tumorali. Queste cellule, come le cellule staminale normali,  hanno la 
capacità, di auto-rinnovarsi, di differenziare in diversi tipi di cellule e di proliferare 
estensivamente. Nel tumore del fegato, le caratteristiche delle CSC  rimangono poco chiare. 
Queste cellule  potrebbero derivare da cellule staminali epatiche residenti o da  cellule 
staminali del midollo osseo. Per la loro identificazione sono stati proposti  diversi marcatori 
molecolari tra i quali CD90, CD44, CD133, EpCAM, e il metodo della  ‘side population’ 
mediante l’espressione di ABCG2 . L'espressione di ABCG2 sembra anche essere  correlata 
con la resistenza ai  farmaci.  
L'obiettivo generale di questo studio è di meglio capire l'eterogeneità delle cellule 
tumorali nel sistema epatico.  A tale scopo sono stati sviluppati  tre progetti interconnessi: 1)  
isolamento  e caratterizzazione delle cellule staminale in diverse parti di tessuti epatici  
neoplastici umani, in particolare  HCC e CC, 2) valutazione dell'espressione di marcatori di 
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cellule staminali in diversi  campioni clinici, 3 )  analisi dell'espressione del trasportatore 
ABCG2 in relazione alle cellule staminali e alla resistenza ai farmaci.  
Abbiamo isolato popolazioni di  cellule sia dai tessuti neoplastici che distali dei pazienti 
con HCC e CC. Queste cellule esprimono i marcatori di superficie CD90 e CD44 ma non il 
marcatore per le cellule staminali emopoietiche CD34. Ulteriori analisi hanno dimostrato che 
queste cellule esprimono  marcatori di superficie mesenchimali e anche  fattori per la  
pluripotenza.  Alcune sottopopolazioni  esprimono anche le citocheratine e a basso livello  
l’albumina. Quando vengono  coltivate a bassa densità, queste cellule  formano colonie simili 
a quelle formate dai fibroblasti suggerendo che queste popolazioni contengono anche  cellule 
mesenchimali. È interessante notare che, quando sono state indotte a trans-differenziare in  
cellule che producono insulina, si è osservata una up-regolazione  dei marcatori delle cellule 
pancreatiche. Inoltre una linea ha dimostrato la capacità di differenziare in adipociti, in 
quanto, se opportunamente indotta, è in grado di accumulare lipidi nel citoplasma oltre a 
mostrare un aumento del gene PPARG. Questi risultati hanno fornito indicazioni del fatto che 
le cellule staminali da tessuti cancerosi poterebbero mantenere la capacità di trans-
differenziare in diverse linee cellulari. In particolare in cellule pancreatiche e adipociti. Come 
atteso, le cellule staminali dai tessuti neoplastici e distali, condividono simili marcatori 
fenotipici. Abbiamo ipotizzato che le differenze tra di esse possano esse a livello intracellulare 
nelle  vie e nei meccanismi molecolari di tali cellule.  
Dal nostro studio sui campioni di tessuto, emerge che la distribuzione dei marcatori delle 
cellule staminali nei tessuti tumorali  è molto variabile. Ciò nonostante si  è osservata una 
tendenza: l’espressione di questi geni è più elevati nei tessuti malati rispetto ai tessuti normali 
e nelle lesioni rispetto ai tessuti distali. Questi risultati  potrebbero indicare  l'esistenza di  
cellule staminali in attiva proliferazione nel tumore e questo processo  potrebbe  
rappresentare il processo di tumorigenesi  che sottende alla trasformazione neoplastica.  
Per quanto riguarda la resistenza ai farmaci, abbiamo osservato che l'espressione di 
ABCG2 in campioni clinici è maggiore nei tessuti neoplastici rispetto ai tessuti distale e ai 
campioni normali derivanti da pazienti giovani. Per supportare i dati in vivo, abbiamo 
impiegato  diverse linee cellulari epatiche in vitro. Abbiamo osservato che l’espressione di 
ABCG2 è significativamente più alta nella linea cellulare  JHH-6: una linea cellulare epatica 
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derivante da un tumore  poco differenziato . Il test dell’ efflusso di substrato Hoechst 33342 
ha inoltre dimostrato che questa linea cellulare ha anche la maggior capacità di eliminare  il 
substrato. In seguito al  trattamento con  doxorubicina, un comune agente anti-neoplastico, è 
stato osservato un aumento di ABCG2 in tutte le linee cellulare epatiche, sopratutto nelle  
linee cellulari con l’espressione basale più bassa.  
Tutti i dati riportati in questo studio hanno rinforzato le prove a favore del’ipotesi della  
presenza di cellule staminali nel tumore al fegato. Questo lavoro potrebbe rappresentare solo  
un piccolo contributo nella conoscenza dell’epatocarcinogenesi e cancerogenesi in generale. 
Tuttavia,  una maggior  caratterizzazione delle cellule staminali normali  e tumorali sarebbe 
molto importante per una miglior  comprensione dei meccanismi di  trasformazione e crescita 
neoplastica. A tale scopo andrebbero chiariti principalmente alcuni aspetti ancora poco 
chiari: per prima cosa sarebbe importante capire come le cellule staminali tumorali sono 
coinvolte nella trasformazione maligna. In secondo luogo sarebbe importante identificare  
marcatori specifici per distinguere le  cellule staminali tumorali dalle cellule staminali 
normali, questi marctatori  potrebbero essere proteine strutturali o proteine di vie 
metaboliche differenzialmente espresse. Un terzo aspetto molto importante è poi la 
comprensione dei meccanismi che sottendono la chemoresistenza al fine di sviluppare 
trattamenti più efficaci. 
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General Introduction 
 
 
 
 
 
 
 
 
 
  Chapter 1 – General Introduction 
 
1 
1.1. Primary Liver Cancer 
1.1.1. Epidemiology and risk factors 
Primary liver cancer (PLC) is the fifth most common neoplasms in the world and the 
third most common cause of cancer-related death. PLC accounted for around 1% of all death 
worldwide (Parkin et al. 2001). Approximately more than 500,000 new cases are diagnosed 
per year, with an age-adjusted worldwide incidence of 5.5–14.9 per 100,000 populations 
(Llovet, Burroughs, and Bruix 2003).  
 
Figure 1.1. Age-standardized incidence rates of the primary liver cancer worldwide. 
Source: GLOBOCAN 2002, picture is taken from (Nordenstedt, White, and El-Serag 2010). 
PLC prevalence is variable distributed, found to be high in Asia and low to high in Europe 
and low to moderate in America continents. Figure 1.1 shows the global distribution of PLC 
with age standardized rate (ASRs). Highest ARS is found in China (ARS > 20.0), Southeast 
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Asia which is endemic to Hepatitis B Virus (HBV) and Japan with Hepatitis C Virus (HCV), 
and sub-Saharan African countries such as Cameroon and Mozambique. Italy has the highest 
incidence in Southern Europe with ASR of 15.9 in men and 5.1 in women (Nordenstedt et al. 
2010). The PLC could be classified into several types based on the primary site of the cancer 
as described in Table 1.1. 
Table 1.1. Types of human primary liver cancer 
PLC types Primary site Frequency  
Hepatocellular Carcinoma Liver parenchyma 85 -90% from all PLC cases 
Cholangiocarcinoma Bile duct 3 -20% from all PLC cases 
Hepatic angiosarcoma or 
hemangiosarcoma 
Blood vessel 2% from all PLC cases 
Hepatoblastoma Liver parenchyma in 
infant and neonatal 
1-4% from all solid childhood 
tumors 
 
Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) accounts for 85% to 90% of PLC cases (El Serag and 
Rudolph 2007). However as shown in Fig.1.1, HCC is not distributed evenly in the world, in 
some area in Asia, HCC is the most common cause of cancer-related mortality (Llovet et al. 
2003).  
Several main risk factors for HCC are widely known. About 80% of all detected cases HCC 
develops in chronic liver disease and cirrhosis is the strongest factor (El Serag and Rudolph 
2007;Llovet et al. 2003) mainly correspond to viral infections Hepatitis B virus (HBV) and 
Hepatitis C virus (HCV), also chemical exposure like excess alcohol consumption, aflatoxin B 
and vinyl-chloride monomer (Mastrangelo et al. 2004), obesity-related disease, and familial-
related disorder such as primary haemochromatosis (Niederau et al. 1985). In almost all 
populations, males have higher cancer rates than females, with male:female ratios usually 
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averaging between 2:1 and 4:1. In HCC relation with ages, female rates peak in the age group 
5 years older than the peak age group for males (El Serag and Rudolph 2007). Until now, the 
relation between smoking tobacco and HCC is not clearly established. 
In Asia and Africa, HBV infection is the highest risk factor of HCC.  The annual mortality 
from hepatitis B infection and its relation is 1-2 million people worldwide (Zuckerman and 
Zuckerman 2000). Until now, over two billions people worldwide have been infected, of 
whom over 350 million are chronic carriers. Some 25% of carriers develop progressive liver 
disease. Chronic HBV carriers have a 100-fold relative risk of developing HCC compared with 
non-carriers, which decreases if infection is acquired in adulthood (Beasley et al. 1981). The 
HBV infections can be prevented by vaccination. The universal Taiwanese HBV vaccine 
program launched in 1984 had significantly decreased the HCC incidence 20 years after 
vaccination (Chang et al. 2009).    
In Europe and North America 50-70% of HCC cased is caused by HCV infection (Llovet et 
al. 2003;Bosch, Ribes, and Borras 1999). About 150 million people (3% of the world's 
population) harbor long-term (chronic) infections with the HCV and about 3–4 million 
people become infected with this virus every year  (Magiorkinis et al. 2009). HCV increases 
HCC risk by promoting fibrosis and eventually cirrhosis. The estimation of HCC development 
from HCV infections is from 1% to 3% after 30 years. If cirrhosis is established, HCC develops 
at an annual rate of 1% to 7% (El Serag and Rudolph 2007). Until now, potent HCV vaccine is 
not yet available and HCV infections can be treated with combination of drugs, but they are 
not real effective in all patients. 
Some other established HCC risk factor is chemical toxins, such us heavy alcohol intake, 
aflatoxin, and vinyl chloride. Among alcohol drinkers in Italy, HCC risk increased in a linear 
fashion with daily intake more than 60 g. The effect of alcohol drinking was evident even in 
the absence of HBV or HCV infection (Donato et al. 2002).  Aflatoxin B1 (AFB1) is a 
mycotoxin produced by Aspergillus fungus. This toxin is mainly found in Asia and sub-
Saharan Africa in which climatic factors and food storage techniques support the fungus to 
contaminate foods, such as grain, corn, peanuts and legumes (Gomaa et al. 2008). Once 
ingested, AFB1 is metabolized to an active intermediate which can bind to DNA and cause 
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damage (Garner, Miller, and Miller 1972). In China, the urinary excretion of aflatoxin 
metabolites was associated with a 4-fold increase in HCC risk. However, in its interaction 
with HBV carriers, the presence of AFB1 had a 60-fold increase risk in HCC (Qian et al. 1994). 
Even though vinyl chloride has been a risk factor, its association with development of HCC 
remains unclear.  
Correlations between HCC and fatty infiltration had been also predicted, represented 
severe forms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis 
(NASH). Several reports had been published proposing the incidences of HCC without any 
identifications of viral infection or heavy alcohol intake. In some way, the development of 
cancer is more likely occur from disease associated with NASH such as diabetes and obesity, 
in which their presence with HCC risk is strongly associated (El-Serag, Tran, and Everhart 
2004;Calle et al. 2003).  
A familial genetic disorder primary haemochromatosis (iron overload), mainly caused by 
C282Y mutation of gene HFE, allows excess iron to be absorbed from the diet. The deposition 
of iron might cause liver fibrosis leading to cirrhosis; however its progression to HCC remains 
unclear. A study from East Anglia showed that only a very small proportion of homozygotes 
for the C282Y mutation developed hepatocellular carcinoma. However, individuals with this 
genotype have a significantly increased risk of this rare disease relative to those who do not 
carry the mutations (Willis et al. 2005). 
Cholangiocarcinoma 
Cholangiocarcinoma (CC), a hepatic tumor originating from bile duct cells, is the second-
most common PLC. It is estimated to be accounted as much as 15% and its incidences varies 
by region (3 – 20%) (Shin et al. 2010). Anatomically, CC can be classified as intrahepatic CC, 
hilar CC, and distal extrahepatic bile duct cancers. Most cases of CC occur sporadically and 
the exact etiology is still unclear. However, the development of CC might be strongly 
associated with chronic inflammation and biliary duct injury, primary sclerosing cholangitis 
or infestation with liver flukes (Opistorchis viverrini, Clonorchis sinensis) (Mosconi et al. 
2009). In Thailand, CC is the most common PLC instead of HCC due to high exposure to liver 
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flukes. In recent years, viral infection might increase the risk of CC in relation with liver 
cirrhosis (Okuda, Nakanuma, and Miyazaki 2002). Surgery is the only potential curative 
treatment of CC. 
Angiosarcoma  
Angiosarcoma is a type of cancer that starts in the blood vessels of the liver, accounting 
2% of all PLCs (Mani and Van Thiel 2001). This cancer is very aggressive and grows fast. Risk 
factor of angiosarcoma is usually unknown, but its development is associated with 
occupational exposure to carcinogens, hemochromatosis and von Recklinghausen disease 
(Bhati et al. 2008;Forbes et al. 1987). In factory workers, vinyl chloride exposure has been 
established with angiosarcoma of the liver, but not other histologics of the liver (El Serag and 
Rudolph 2007;Boffetta et al. 2003). Treatment may be used to slow the progression the 
disease but life expectancy and prognosis are usually low. 
Hepatoblastoma 
Hepatoblastoma (HB) is the most common liver cancer in children and infant, 
approximately more than 1% of all childhood malignancies. This tumour is rare and usually 
not detected on early stages until they formed a large abdominal mass and spread to other 
tissues (Finegold et al. 2008). Immunnohistologically, HB cells shows various epithelial or 
mesenchymal lineages of differentiation (Abenoza et al. 1987). The epithelial components of 
hepatoblastomas exhibit features of embryonal and fetal liver differentiation (Ishak and 
Glunz 1967). Like adult liver cancers, complete liver resection is necessity for the cure and the 
goal of therapy.  
 
1.1.2. Treatments 
The HCC staging system had been described according to Barcelona-Clinic-Liver-Cancer 
(BCLC) (Llovet, Bru, and Bruix 1999), Cancer of the liver Italian Program (CLIP) (1998), 
TNM (tumor, node, and metastasis) (Lei et al. 2006), Okuda (Okuda et al. 1985), and 
Japanese Integrated Staging (JIS) (Kudo, Chung, and Osaki 2003) score. Recently, the BCLC 
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system has became the basis for international guideline for HCC treatments (Llovet et al. 
2003).  
Until now, main curative treatments for the PLC are surgical procedures such as liver 
transplantation or partial liver resection, local ablation and trans-arterial therapies. However, 
these treatments are curative only for a small number of patients with early stages and 
monofocal diseases when patients have good life expectancy. Furthermore, potential 
candidate patient for surgical treatment must be carefully selected based on liver function.   
Most of the patients with more advanced stages and severe cirrhosis could only receive 
systemic chemotherapies or supportive treatments. For HCC patients who cannot receive any 
surgical interventions, the survival has not significantly increased in the past 30 years (Blum 
2005).  Many chemotherapeutic agents have been tested but the response rate was still low, 
ranging between 10% and 15% (Abou-Alfa et al. 2008). Unfortunately, most PLC patients 
have poor survival prospect with median survival is estimated at less than 1 year. Low survival 
rate is associated with delayed observation that most of cases are detectable in late stages, 
aggressive disease and therapy failure. 
One of the most studied chemotherapeutic agents for HCC treatment for more than 30 
years is doxorubicin. A report from phase III trial in un-resectable HCC patients compared 
the administration of doxorubicin as single-agent therapy and combination regimen therapy 
PIAF (cisplatin/interferon/doxorubicin [Adriamycin]/5-fluoruacil [5-FU]). Although patients 
on PIAF showed a higher overall response rate than patients on doxorubicin alone, the 
difference was not significant (Yeo et al. 2005). The exact mechanism of action of doxorubicin 
is supposed to intercalate with cell’s DNA and inhibit biosynthesis (Momparler et al. 1976). 
Doxorubicin restrains the progression of the enzyme topoisomerase II, which relaxes 
supercoils in DNA for transcription. Doxorubicin stabilizes the topoisomerase II complex 
after it has broken the DNA chain for replication, preventing the DNA double helix from 
being resealed and thereby stopping the process of replication. 
Many chemotherapy drugs as a single agent or combinations therapy have been 
introduced to treat HCC. Some of the most studied drugs are described in Table 1.2.  
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Table 1.2. Several current chemotherapy agents for HCC treatment 
Agent Mechanisms 
Doxorubicin Inhibits the progression of the enzyme topoisomerase II and 
discontinue replication of the cells 
Etoposide Inhibits the enzyme topoisomerase II 
Cisplatin Crosslinks DNA and interferes cell division 
Gemtacitabine Act as nucleoside analog and target the enzyme enzyme 
ribonucleotide reductase 
Mitoxantrone Inhibits the enzyme topoisomerase II 
Paclitaxel Hyper-stabilizes the microtubule and induces apoptosis by binding 
to protein Bcl-2 
Irinotecan Inhibits the enzyme topoisomerase I 
 
1.2. Cancer Stem Cells Theory 
1.2.1. Sources of stem cells 
The stem cells are the unspecialized cells which give rise to multiple cell types in the body. 
The stem cells have specific properties of ability to self-renew through cell division for long 
period, capability to differentiate into multiple lineages, and potential to proliferate 
extensively. There are three main sources of stem cells that can be obtained from human 
organism: embryonic stem cells, adult stem cells, and induced-pluripotent stem cells as 
shown in Figure 1.2. These cells have their own characteristic and potentials. 
The human embryonic stem cells (hESCs) are derived from the embryo, typically from 
inner cell mass in the blastocyst. These cells are considered to be most pluripotent and can 
become all cell types in the body. The isolation and cultivation of hESCs have opened the 
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prospect of cell and tissue engineering in human body, mainly in future treatment of 
untreatable diseases. Due to its pluripotential, the hESCs would be potent tools in 
regenerative medicine such as Parkinson’s disease, spinal cord injury, myocardial infarction, 
and many more (Mountford 2008).  During the embryonic development, pluripotent hESCs 
give rise to somatic stem cells that further differentiate into multipotent tissue-specific stem 
or progenitor cells. 
The adult stem cells or somatic stem cells (hASCs) are small number of undifferentiated 
cells found in a specific area of tissue or organ. They are activated by disease or severe tissue 
injury and function to repair that specific tissue from severe damage. The multipotency of the 
hASCs is less than hESCs, mainly they can differentiate into cells of their host tissues. For 
example, haematopietic stem cells give rise to all blood cells; bone marrow stromal cells 
(mesenchymal cells) to osteocytes, chondrocytes, and adipocytes; neural stem cells to 
neurons, astrocytes, and oligodendrocytes. However, many kinds of stem cells from adult 
tissues seem to have the ability to differentiate into different cells.  Reported human 
multipotent adult stem cells (hMASCs) from liver, heart, and bone marrow had shown to 
exhibit a wide range of differentiation potential, both in morphological and functional level 
(Beltrami et al. 2007). 
The most recent induced pluripotent stem cells (iPS) from adult cell were first reported 
by Yamanaka & Takahashi in 2006. By using four defined transcription factors Oct3/4, Sox2, 
c-Myc, and Klf4, mouse fibroblasts were reprogrammed into embryonic stage. These iPS cells 
exhibited ES morphology and growth properties and ES cell marker genes. Furthermore 
subcutaneous transplantation of iPS cells into nude mice resulted in tumors containing a 
variety of tissues from all three germ layers (Takahashi and Yamanaka 2006). Consequently, 
many studies have been carried out based on this technique of reprogramming human cells 
from fetal, neonatal and adult human primary cells, including dermal fibroblasts, to 
pluripotency states (Park et al. 2008). Because of its embryonic stem cells-like pluripotency, 
the iPS might be valuable tools for the research of the mechanisms of tissue formation, cells 
therapy, and patient-specific cells development in the futures.  
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Figure 1.2. Sources of embryonic, adult stem cells, and induced pluripotent stem cells. 
Human stem cells can be classified based on their sources as hESCs from the embryo, hASCs from adult 
tissues, and iPS from re-programmed mature cells to embryonic-like cells.   
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1.2.2. Hepatic stem cells 
Liver is a largest internal organ in human body which has high regenerative potential. In 
minor damage, hepatocytes can divide and repair the damage. In adult liver, mature 
hepatocytes seldom proliferate and have a life span of over a year. However, after partial 
hepatoctomy, proliferation of quiescent hepatocytes and cholangiocytes, followed by 
proliferation of hepatic stellate cells and endothelial cells, quickly restores the liver into its 
original mass (Mishra et al. 2009). In severe major damage, hepatic stem cells will be 
activated to replenish the injury in the liver. Moreover, these cells rarely acquire age-related 
genetic defects associated with cancer induction that may imply their protective mechanism 
against genetic damage (Mishra et al. 2009). The origin of stem cells in the liver has been a 
subject of discussion on whether they are real resident hepatic stem cells or derived from 
bone marrow stem cells migrated to the liver.  
The common normal hepatic stem/progenitor cells have been proposed to be localized at 
the junction of the bile ducts and hepatic cords, known as canal of Hering (CoH) (Theise et al. 
1999;Sell 1993;Sell and Leffert 2008). The Canal of Hering (CoH) represents anatomic and 
physiological link between intralobular canalicular system of hepatocytes and the biliary tree 
(Figure 1.3). The reside cells in CoH showed shared morphology and immunophenotye 
between hepatocytes and cholangiocytes.  They are positive for cytokeratin CK7 and CK19, 
oval cell markers OV6 and OV1, neuroendocrine markers chromogranin-A, neural cell 
adhesion molecule, and many others.  
The hepatic/progenitor stem cells give rise to hepatoblast, dominant cell type in fetal and 
neonatal liver, and along organ maturation will differentiate into hepatocytes and 
cholangiocytes (Schmelzer, Wauthier, and Reid 2006). When mature hepatocytes or 
cholangiocytes are damaged or inhibited in their replication, this reserve compartment of 
hepatic stem/progenitor cells is activated, referred as ‘ductular reaction’ in human and ‘oval 
cell’ reaction in rodents. Alpha fetoprotein (AFP) is one of the earliest markers detected in the 
liver bud developed from ventral foregut. Recent studies also showed that EpCAM, an 
epithelial adhesion molecule, is a biomarker for hepatic stem cells and hepatoblasts. 
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Figure 1.3. The Canal of Hering as resident hepatic stem cells niche in human liver. The 
Canal of Hering (CoH) which represents connection between bile canaculi and bile duct is the location 
and niche for stem/progenitor cells. Scheme of CoH is taken from Peng et al. Stem Cell (2010).  
 
However, a subpopulation of ductular cells also expresses markers of haematopoietic cells 
such as CD34 and CD90 which might be directly originated from bone marrow (Roskams 
2006). Bone marrow-derived cells could be source for oval cells (Petersen et al. 1999) and 
may contribute in liver regeneration through positive selective pressure through trans-
differentiation capacity or fusion from bone-marrow derived cells with hepatocytes (Lee et al. 
2009).  
Furthermore, the identification and distribution of MSCs in many adult human tissues 
been demonstrated. Interestingly, these MSCs reside in a diverse host of tissues and posses 
the ability to generate tissue-specific cell types. The characteristic of MSCs, self-renewal, 
differentiation capacity and cell niche is reviewed in (Kolf, Cho, and Tuan 2007).  In human 
adult liver, isolated MSCs have capacity to differentiate into mature hepatocytes, even to 
osteogenic and endothelial lineages. Furthermore they contributed to the regeneration of liver 
parenchyma in immunodeficient mice (Herrera et al. 2006). 
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1.2.3. CSCs theory in liver cancer 
Carcinogenesis (development and progression of cancer) is consisted of many steps and 
long term courses from normal to malignant tissues. There are two main theories of initiation 
of cancer. The stochastic model proposes that cancer occurs due to a random process and all 
the cells in the body of tumor have capacity to initiate cancer.  
A more recent theory proposed that cancer is composed in a hierarchy and only a small 
population of the cells in the cancer has capacity to initiate and maintain tumor growth. Just 
as normal stem cells in normal tissue, CSCs perform as stem cells in cancerous tissue. These 
cells act as the main players in the highest level of the cancer hierarchy and may still have 
stem cells properties such as self-renewal and ability to multiple cell types.  According to this 
CSCs theory, cancer mass is assembled in heterogeneous populations of cells: malignant CSCs 
as central populations with the capacity to divide and differentiate and partial or full 
differentiated cancer cells derived from CSCs that comprise the majority of cancer mass. This 
hierarchy model proposes that only CSCs population is gifted with special and unique 
protective mechanisms to be responsible for the maintenance and propagation of the tumor 
(Ma, Chan, and Guan 2008).  
Many cancers are found to be very heterogeneous and contain many cell types. The first 
conclusive evidence of cancer stem cells was demonstrated by the group of John Dick in mid 
1990’s in acute myeloid leukemia (AML) cells in which a CD34+/CD138- subpopulation is 
capable in initiating tumors in NOD/SCID mice (Lapidot et al. 1994;Bonnet and Dick 1997). 
After this breakthrough, many reports had demonstrated the proofs of tumor initiating cells 
both in hematopoietic cancer and solid tumors. In solid tumors, the cancer stem cells have 
been found in breast tumor, brain tumor, colon cancer, pancreatic tumor, ovarian cancer, 
melanoma, lung cancer and many others. The CSCs had been identified in almost all human 
cancers.  
In liver cancer, CSCs with various markers had been purified from established cancer cell 
lines and primary tumor. However until now, there is no definite agreement of specific CSCs 
markers for liver cancer due to wide risk factors, cancer types, and prognostic groups. Several 
studies had reported the association of these cells with clonal activity, aggressive growth, 
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tumor induction capacity and chemoresistance.  However, one of the important stem cells 
characteristics, the multilineages differentiation potential, is still unclear.  
The first evidence of CSCs existence in liver cancer was reported in 2005 by Haraguchi 
and colleagues when they isolated side population (SP) cells of HCC cell lines Huh7 and 
Hep3B. Huh7 SP cells were found to be more resistant to anticancer drugs such as 
doxorubicin, 5-flouracil, and gemcitabine, compared to non-SP cells (Haraguchi et al. 
2006b;Haraguchi et al. 2006a). Another evidence of SP in HCC was also provided by Chiba et 
al.  in which transplantation of as few as 1000 cells successfully induced tumor in NOD/SCID 
mouse (Chiba et al. 2006).  
The search of CSCs in liver had progressed and developed. In late 2006, CD133 was 
proposed to be a CSCs surface marker to isolate CSCs population from HCC cell line. Further 
evidences of CD133 as hepatic CSCs marker had been also exhibited in several reports (Ma et 
al. 2007;Ma et al. 2008a;Ma et al. 2008b;Yin et al. 2007;Zhu et al. 2010). In 2008, Yang et 
al. give a wider outlook and exhibit that CD90 cells isolated from hepatic cell line, primary 
cancer, and peripheral blood have also distinct characteristic as CSCs (Yang et al. 
2008b;Yang et al. 2008a).   
Because CSCs are important in the initiation and maintenance of the cancer, their 
resistance to anticancer drugs is an obstacle for the total eradication of cancer. Conventional 
chemotherapies may recognize and kill most of bulk (differentiated) tumor cells but spare the 
CSCs. Therefore to achieve a complete response in liver cancer therapy it is crucial to target 
the CSCs first to eradicate the source of the cancer, and then the more differentiated tumor 
cells (Figure 1.4). Total eradication of the tumor will not only reduced the differentiated 
tumor size, but more importantly to prevent the reoccurrence of cancer (Dean, Fojo, and 
Bates 2005). 
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Figure 1. 4. Initiation and progression of the CSCs in cancer. The CSCs might be derived from 
mutation in normal SCs developing cancerous SCs with SCs potentials. Consequently, CSCs induce 
tumors, maintain it, and create metastasis. The CSCs were also thought to be resistant to conventional 
chemotherapies. 
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1.2.4. Hepatic CSCs marker 
Stem cells marker is a specialized signaling molecule or protein receptor that mainly 
coating the surface of cell which allow the identification and differentiation one cell to other 
cells. As had mentioned, the definite characteristic of the CSCs in liver cancer is still debatable 
and unclear. Because of the wide variability of HCC risk factors and long term development, 
the characteristic of HCC between individuals are sometimes unique and variable. Besides 
that, the heterogeneity is not only between HCCs but also within given tumor, in which the 
more-differentiated cells usually occur via the emergence of less-differentiated clonal areas 
within the tumor (Saeki et al. 2000).  
Table 1.3. Several markers for hepatic CSCs identification 
Models Markers Function Frequency Origin 
Cell 
lines  
CD90+  Cell-cell interaction, adhesion 0.1 – 1.9 %  MSC/HSC/HPSC  
CD133+  unknown 0.1 – 90.0 %  Immature HSC  
 CD133+ ALDH+  ALDH is responsible for 
oxidation of intracellular 
aldehydes 
0.9 – 55.7 %  HSC  
 EpCAM+ Adhesion molecule 58.1 – 99.2%  Epithelial/early 
progenitor  
 OV6+ antibody Recognize cytokeratin 0.2 – 3.0 %  Biliary cells/ SEC  
 Side population  Cells defense mechanism 
against chemotherapies 
0.3 – 0.8%  Diverse  
Primary 
cancer  
CD90+ CD45-  Cell-cell interaction, adhesion 0.7 – 4.2%  MSC  
 CD90+ CD133+  Cell-cell interaction, adhesion 1 sample  MSC/HSC  
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Several studies had proposed different markers to identify CSCs populations such as 
surface markers CD90 (Thy-1), CD133 (Prom-1) and EpCAM, oval cells antibody OV-6, and 
side populations (SP) phenotype. The list of hepatic CSCs is summarized in Table 1.3.  
CD90 (THY-1) 
CD90 is a 25-37 kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed 
in many cell types such as T cells, thymocytes, neurons, endothelial cells, and fibroblast. It 
has function as an important regulator of cell-cell and cell-matrix interaction, apoptosis, 
adhesion, migration, cancer, and fibrosis (Rege and Hagood 2006). CD90 is also expressed in 
bone-marrow derived stem cells (Dennis et al. 2007), hepatic stem/progenitor cells both in 
adult or fetal livers, but not in adult hepatocytes (Herrera et al. 2006;Dan et al. 2006;Lazaro 
et al. 2003).  From fetal liver, CD90+CD34+CD117+ cells can be differentiated into adult liver 
cells (hepatocytes and cholangiocytes) and mesenchymal lineage adipogenic and osteogenic, 
and endothelial differentiation (Dan et al. 2006). From normal adult liver, cells with 
phenotype CD90+CD44+CD29+CD73+ had also osteogenic and endothelial potential 
differentiation, and even could be induced into pancreatic islet-like structures (Herrera et al. 
2006).  
In systemic cancer T-acute lymphoblastic leukemia (T-ALL), a small subpopulation of 
CD90+/CD110+ which expressed in haematopoietic stem cells were shown to correlate with 
stem cell properties both in vitro and in transplantation experiments. These markers are 
useful positive-selection markers for the isolation of CSCs in some cases of T-ALL (Yamazaki 
et al. 2009).  
In solid tumor like HCC, cells expressed CD90+ had been purified from hepatic 
cancerous cell lines and primary cancers. The CD90+ cells but not CD90- cells from HCC cell 
lines HepG2, Hep3B, PLC, HuH-7, MHCC97L, and MHCC97H displayed tumorigenic 
capacity when they were injected into immunodeficient mice (Yang et al. 2008a). From 
primary tumors, CD90+CD45- cells from the tumor tissues and blood samples of liver cancer 
patients also have capacity to generate tumor nodules in mice. Furthermore, CD90+CD45- 
cells were detectable in 90% of blood samples from cancer patients but none in normal 
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subjects or patients with cirrhosis indicates circulating CSCs in human liver cancer (Yang et 
al. 2008b). 
CD133 (Prominin-1) 
CD133 (prominin-1) is a member of pentaspan transmembrane glycoprotein family. 
Human surface antigen AC133, a homologue for mouse prominin-1, was discovered by 
generating a monoclonal antibody to CD34+ hematopoietic stem cells isolated from fetal 
liver, bone marrow, and cord blood (Yin et al. 1997). Human prominin-1 consisted of 865 
amino acids (aa) with a total molecule weight of 120 kDa (115 kDA in mouse). Prominin-1 has 
a unique structure composed of an N-terminal extracellular domain, five transmembrane 
domains with two large extracellular loops, and a 59 aa cytoplasmic tail. Until now, the main 
function of prominin-1 remains unclear (Shmelkov et al. 2005).  
CD133 is one of the most common CSCs markers in solid tumors. It is often expressed in 
adult stem cells and has function in suppressing cells differentiation. The evidence of CD133 
as CSCs marker had been demonstrated in solid tumor such as brain cancer (Singh et al. 
2004;Singh et al. 2003), prostate cancer (Miki et al. 2007), colon cancer (O'Brien et al. 
2007), and pancreatic cancer (Hermann et al. 2007).  
In liver cancer, CD133 is proposed to be a marker mainly in hepatic cell lines. Cells 
CD133+ purified from cell lines SMMC-7721, Huh-7 and PLC8024 were able to induce tumors 
in xenograft models in contrast with their CD133- counterpart (Suetsugu et al. 2006;Ma et al. 
2007;Yin et al. 2007). Following cells-directed differentiation, CD133+ cells showed a 
dramatic increase of angiomyogenic markers, suggesting potential to skeletal and cardiac 
features differentiation (Ma et al. 2007). In combination with aldehyde-dehydrogenase 
(ALDH), CD133+ ALDH+ cells were significantly more tumorigenic than their CD133+ALDH- 
or CD133-ALDH- (Ma et al. 2008a).  In connection with chemoresistance, CD133+ cells 
activate the preferential Akt/PKB and Bcl-2 as survival response (Ma et al. 2008b). A recent 
report exhibited that combination CD133+CD44+ cells have extensive proliferation, self-
renewal, and differentiation into the bulk of cancer cells. In vivo xenograft experiments 
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revealed that the highly tumorigenic capacity was primarily attributed to CD133+CD44+ cells 
instead of their CD133+CD44- (Zhu et al. 2010).  
EpCAM 
The name EpCAM derives from the original functional description as a glycoprotein 
epithelial cell adhesion molecule. Structurally, EpCAM is closely related to one 
transmembrane glycoprotein GA733-1, both are novel proteins in structure and likely 
function (Litvinov et al. 1994). The gene EpCAM contains nine exons with extracellular, 
transmembrane, and cytoplasmic components (Linnenbach et al. 1993).  EpCAM has been 
shown to be expressed on the basolateral cell surface of selected normal epithelia and many 
carcinomas (Armstrong and Eck 2003). 
EpCAM is a recent marker used to identify the CSCs in liver cancer. EpCAM gene encodes 
a carcinoma-associated antigen and is expressed on most normal epithelial cells and 
gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion 
molecule. The antigen is being used as a target for immunotherapy treatment of human 
carcinomas.  
Yamashita et al. reported that EpCAM expression in HCC displayed a distinct molecular 
feature with features of stem markers, whereas HCC without EpCAM expression displayed 
genes with features of mature hepatocytes (Yamashita et al. 2008). The isolation of EpCAM+ 
cells had also been performed from both HCC cell line and primary cancers. These isolated 
cells had displayed hepatic CSCs-like capacity including self-renewal capacity, differentiation, 
and tumor induction in NOD/SCID mice (Yamashita et al. 2009;Kimura et al. 2010). 
Furthermore, EpCAM has been shown to be a direct transcriptional target in the Wnt/β-
catenin pathway that has been suggested to have an important in the self-renewal of cancer 
cells (Yamashita et al.2007). 
OV-6 antibody 
The OV-6 monoclonal antibody had been developed after treatment with hepatotoxins or 
hepatocarcinogens in rat and is a useful marker to oval cells and hepatoma cells (Dunsford 
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and Sell 1989;Dunsford et al. 1989). The positivity of OV-6 had been observed in fetal liver 
and adult biliary disease, adult liver disease, and pediatric liver disease. The antigen target of 
OV-6, the oval cells, shared epitope with CK14 and CK19 (Libbrecht et al. 2001). Several 
studies have shown a progenitor cell with OV-6 reactivity in a substantial number of HCCs. 
These cells are thought to be derived from hepatic stem cells in the intraportal area and they 
have ability to differentiate into hepatocytes and biliary cells. 
ABCG2 
Simultaneously with the progression of molecular techniques, the ABCG2 expression had 
been closely related with cells differentiation and stem/cancer stem cells. This marker is 
related with a distinct phenotype of stem cells, commonly known as side population, 
associated with its function as protective protein against chemotherapies. More detail of 
ABCG2 as a marker of CSCs in hepatic system is further described in chapter 1.4.  
1.2.5. Plasticity 
Until now, many reports demonstrated capacity of SCs from both fetal and adult tissues 
to differentiate into other cells, even other lineages. In the other hand, trans-differentiation 
data of CSCs or SCs from cancerous tissues into other lineages are still limited. This 
restriction capacity of the CSCs might be caused by changes in cell ‘stemness’ pathway which 
constrain cells plasticity. However, it is important to study the possible trans-differentiation 
potency of the CSCs (Table 1.3). This capacity is associated with function of these cells in the 
cancerous tissues and also might be related with their metastatis capacity. 
As reported, cells with phenotype CD90+, CD44+, CD29+, CD73+ from normal adult 
liver tissues can be differentiated into mesenchymal lineage osteogenic cells, even to 
endodermal cells such as pancreatic islet.  From fetal liver, cells CD90+, CD34+, CD117+ can 
be induced into adult liver cells, mesenchymal lineages, and endothelial cells.  
From HCC cell line, CD133 cells also have potency to up-regulate several marker genes of 
angiomyogenic cells. A recent report showed that CD133+ cells purified from rat hepatic 
stellate cells could trans-differentiated into several other cell types (Kordes et al. 2007). 
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Hepatic stellate cells possess signaling pathways important for maintenance of stemness and 
cell differentiation, such as hedgehog, beta-catenin-dependent Wnt, and Notch signaling, and 
are resistant to CD95-mediated apoptosis. Moreover, stellate cells display a differentiation 
potential as investigated in vitro and in vivo. Collectively all these properties are congruently 
found in stem/progenitor cells and support the concept that stellate cells are undifferentiated 
cells, which might play an important role in liver regeneration (Kordes, Sawitza, and 
Haussinger 2009). Stellate cells are activated and responsible to develop liver fibrosis and 
progress to cirrhosis. These data indicate that in humans, liver cirrhosis leads to recruitment 
of various populations of hematopoietic progenitor cells that display markers of intrahepatic 
progenitor cells (Gehling et al. 2010).  
 
Table 1.4. Current data of trans-differentiation study of SCs from fetal and adult liver 
 Sources  Phenotype  Differentiation  Reference  
Normal 
SCs  
Adult human 
liver  
CD90
+
, CD44
+
, 
CD29
+
, CD73
+ 
 
Endothelial, osteogenic, 
and islet-like structures  
(Herrera et al. 
2006) 
 Fetal human 
liver  
CD90
+
, CD34
+
, 
CD117
+
 
Liver cells; adipogenic, 
osteogenic, endothelial  
(Dan et al. 2006) 
 Fetal human 
liver  
CD34
+
, CD117
+
 Mature liver cells  (Nowak et al. 
2005) 
 Adult rat liver  CD90
+ 
 Pancreatic cells  (Yang et al. 2002) 
Cancer 
SCs  
Cell lines and 
primary 
cancers  
CD90
+ 
  no data
 
 (Yang et al. 
2008b) 
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 Cell lines  CD133
+ 
 Angiomyogenic cells  (Ma et al. 2007) 
 HepG2 cell line 
(+ plasmid)  
no data Pancreatic cells  (Li et al. 2005) 
 
 
1.3. Tumor Microenvironment: CAFs 
Stroma is interposed between cancerous cells and normal tissues. Stroma is induced as a 
result of tumor-host interaction or cross-talk and it is essential to support tumor growth by 
providing access to nutrients or disposal. The components of the stroma are vital for cancer 
initiation, growth and progression. Furthermore they might be sources of information for 
prognostic or targeting response-predictive (Pietras and Ostman 2010). This information 
leads to a further details of cancer biology that cancer cells itself might be not enough to 
invade its surrounding and carcinogenesis needs environment support. 
Recent studies have demonstrated the importance of cross-talk between cancer cells and 
its surrounding stromal microenvironment in liver cancer. Tumor environment mainly 
consists of cellular components such as fibroblasts, stellate cells, immune cells, and 
endothelial cells. These cells provide non-cellular components: growth factors including 
transforming growth factor β1 (TGF- β1) and platelet derived growth factor (PDGF), 
proteolytic enzymes such as matrix metalloproteinases (MMPs) and tissue inhibitor 
metalloproteinases (TIMPs), extracellular matrix (ECM) proteins and inflammatory 
cytokines. The non-cellular components modulate signalling pathways, tumor invasion, and 
metastasis (Yang, Nakamura, and Roberts 2010). 
Hepatocarciogenesis involves alteration of cell signalling molecules and might be 
associated with epithelial to mesenchymal transition (EMT). EMT is a process when epithelial 
cells changed their characteristics to be closer to mesenchymal cells. EMT is more well-known 
in embryonic development, but currently is also considered to play an important role in 
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cancer, specifically in invasion and metastasis. Studies of EMT are mainly performed in 
breast cancer. 
Hepatic stellate cells are major cell type for collagen synthesis in the liver. These cells will 
be activated in response to damage in the liver and trans-differentiated into myofibroblast-
like cells resulting to liver fibrosis and extensive accumulation of ECM. Interestingly, hepatic 
stellate cells also promote proliferation HCC cells. Conditioned medium collected from 
stellate cells significantly induced HCC proliferation and migration in vitro and promoted 
tumor growth in vivo (Amann et al. 2009).  
 
 
 
 
 
 
 
 
 
Figure 1.5. The role of cancer-associated fibroblasts in cross-talk interaction between 
cancer cells and tumor microenvironment. Scheme is taken from (Franco et al. 2010) 
Cancer-associated fibroblasts (CAFs) or sometimes acknowledged as cancer stromal cells 
are the most important cell type in the stroma. They are activated by TGF-β and are 
responsible for the synthesis, deposition, and modelling of excessive ECM  (Yang et al. 2010). 
Furthermore, they secrete soluble factors that influence all cells in the stroma including 
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angiogenesis enhancement and tumor immunity (Rasanen and Vaheri 2010). However, CAFs 
characteristic remains poor defined even though usually it is defined by the expression of 
vimentin and α-smooth muscle actin (α-SMA). Moreover, the origin of these cells is still 
unclear and might be derived from several sources. 
First evidence of tumor-stimulating property of the CAFs was demonstrated from human 
prostate cancer by group of Tlsty and Cunha in 1999. The mixture of fibroblasts from cancer 
and initiated, nontumorigenic prostate epithelial cells dramatically stimulated growth and 
altered histology in immunodeficient mice, while this result was not detected of mixture with 
normal fibroblasts. However, CAFs did not affect growth of normal epithelial cells (Olumi et 
al. 1999). Further study in breast cancer showed similar properties in inducing tumor growth 
significantly by secreting stromal cell-derived factor 1. Moreover, cultured CAFs expressed 
traits of activated fibroblasts (myofibroblasts) with increased of α-SMA (Orimo et al. 2005). 
However, information of tumor-stromal interaction in HCC is still limited. A recent study 
demonstrated a cross-talk between malignant hepatocytes and myofibroblasts in co-
transplantation in vivo. They demonstrated that tumor cells invasion diminished after TGF-β 
and PDGF interference, proposing a very important function of these two factors in tumor 
growth and EMT (van et al. 2009). Hepatic myofibroblasts are proposed to be originated 
through activation of hepatic stellate cells, portal fibroblasts and bone marrow-derived MSCs 
during liver injury and liver cancers. However, the nomenclature of myofibroblast is complex. 
Several reports use the term myofibroblast for both myofibroblast-like and myofibroblast and 
this may cause misunderstanding in tracing the origin of these cells.  CAFs express α-SMA 
which is a characteristic of hepatic myofibroblasts in chronic liver injury. It is reported in rat 
liver fibrosis that CD90 is expressed in myofibroblasts or activated hepatic stellate cells 
during cells proliferation (Dezso et al. 2007).  
The sources of hepatic myofibroblasts are thought to be originated from activated hepatic 
stellate cells, portal fibroblasts, or bone marrow-derived stem cells during liver injury. A 
recent paper using mouse model demonstrated cross-talk between malignant hepatocytes and 
myofibroblasts in co-transplantation in vivo. Furthermore, they showed that tumor cells 
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invasion diminished after TGF-β and PDGF interference, proposing a very important function 
of these two factors in tumor growth EMT (van et al. 2009). 
Adult MSCs are a potential candidate cell type for the study of regenerative medicine. The 
existence of MSCs as bone-marrow derived cells in normal adult liver and maybe in cancerous 
liver may provide new understanding in the maintenance and homeostatis of the tumor. 
Phenotipically and functionally, they fit with requirements of supporting cells CAFs (Franco 
et al. 2010). For example, in pancreatic cancer, MSCs can contribute to one forth of total 
myofibroblast of total stroma (Ishii et al. 2003). 
From clinical point of view, interaction between tumor and stroma has been interesting 
target for HCC treatment. The basis of this system is to attack property of tumor 
microenvironment that acts as supplier of the tumor needs. Targeting this specific molecule is 
conducted simultaneously with conventional chemotheraphy that focus directly tumor cells or 
CSCs. 
Several drugs inhibit angiogenesis and disrupt tumor-stromal interaction is one of the 
promising therapeutic agents for HCC. Sorafenib, a multi-tyrosine kinase inhibitor including 
VEGFR-2, VEGFR-3 targeting, as well raf kinase, is currently standard of care for patients 
with advanced stages. It was demonstrated prolong median survival and time to progression 
by nearly 3 months in patients with advanced HCC in a large phase III trial (Llovet et al. 
2008). Another inhibitor on phase II clinical trial sunitinib had demonstrated tolerability and 
efficacy in patients with advanced HCC (Faivre et al. 2007). Bevacizumab, a recombinant 
monoclonal antibody against VEGF is also used as single or combination therapy agent 
(Siegel et al. 2008). Combination of bevacizumab and erlotinib in advanced HCC patients 
showed significant anti-tumor activity (Thomas et al. 2009). Still, further evaluation is 
needed to avoid the negative side effects of agents. More recently, LY2109761 was shown to 
inhibit tumor specific neoangiogenesis and furthermore, to interrupt the cross-talk between 
HCC cells and CAFs, thus inhibiting tumor progression (Mazzocca et al. 2010). 
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1.4. CSCs Markers and Clinical Significances in Liver Disease  
 
Beside the use of stem cells markers as described above to identify and isolate population 
of CSCs in hepatic cell lines and primary cancers, these markers might have also clinical 
significances in liver diseases, correlating with bad or good prognosis in patients. However, 
due to the PLCs wide risk factors and individual uniqueness, they may consist of many 
distinct molecular characteristics. As predicted, the expressions of CSCs in human liver 
diseases were found to be highly variable. But collectively, their expressions whether weak- or 
strong-correlated with liver cancer compared to normal liver may support the CSCs 
hypothesis.  
An elegant study by Lee et al. demonstrated new prognostic types of HCC. Using a global 
integrated gene expression data, individuals with HCC who shared a gene expression pattern 
with fetal hepatoblast (HB subtype, cluster A) had poor prognosis compared to individuals 
with hepatocyte pattern (HC subtype, cluster B). The expression of expression of well-known 
markers of hepatic oval cells, the early progenitors of adult liver stem cells, is found in the HB 
subtype of HCC. HCC with fetal hepatoblast subtype may arise from hepatic progenitor cells 
(Lee et al. 2006).  
EpCAM had been reported to be expressed mostly in CC and less in HCC (de Boer et al. 
1999).  A high throughput analysis identified that based on this marker, HCC can be divided 
into EpCAM+ subtype with molecular signature of hepatic progenitor cells (Hepatic Stem-like 
HCC; HpSC-HCC) and EpCAM-  subtype with features of mature hepatocytes (Mature 
Hepatocyte-like HCC; MH-HC).  In addition, by determining the level of AFP, HCC could be 
sub-classified into four groups with prognostic implications. EpCAM+ AFP+ HCC has poor 
prognosis compared to EpCAM−AFP− HCC (Yamashita et al. 2008).  
Nonetheless, even the use of single CSCs marker such as CD90, CD133, and EpCAM had 
also been attempted in its correlation with clinical prognostic significance. Based on literature 
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reviews in current biomedical database, the association between CSCs marker and their 
clinical significance is summarized in Table 1.5. 
Table 1.5. The CSCs marker in human liver cancer tissues and their clinical significances. 
Markers Expression in liver cancer 
tissues 
Clinical significance References 
CD90  (+) majority in poor-
differentiated HCC  
  Poor prognosis (Yu et al. 2011;Lingala et al. 
2010; Lu et al. 2011) 
CD133  (+/-) found frequently  ↓ disease survival  (Yu et al. 2011;Song et al. 
2008) 
EpCAM  (-) majority HCC ; (+) CC  ↑ poor prognosis  (Yamashita et al. 2008;de 
Boer et al. 1999;Kim et al. 
2004)  
ABCG2  (+); ↑ after treatment and 
tumoral  
   (Zen et al. 2007;Vander et 
al. 2008;Vander et al. 
2006;Sun et al. 2010)  
OCT4  ↑ tumoral tissues ↓ disease survival  (Yuan et al. 2010;Huang et 
al. 2010)  
CK7  protein (+/-)      (Durnez et al. 2006) 
CK19  protein (+/-)  worse prognosis, 
recurrence  
(Durnez et al. 2006;Uenishi 
et al. 2003)  
 
 
In neuroblastoma CD90- patients have a significantly impaired overall survival compared 
to CD90+ patients (Fiegel et al. 2008). In contrast, CD90+ expression in acute myeloid 
leukemia (AML) is related with unfavorable clinical and biological features, indicating the use 
  Chapter 1 – General Introduction 
 
27 
of CD90 as an additional marker of AML prognostic value (Buccisano et al. 2004). In liver 
disease, information of CD90 with its clinical significance is not available, however CD90 
expression was found preferably in poor differentiated HCC (Yu et al. 2011). A recent report 
from immunohistochemical data showed that CD90 protein was increased in 73% of HCC 
samples. CD90 expression was not influenced by chronic alcohol exposure or cirrhosis. Over-
expression in CD90 was correlated with age, HBV infection, and histological grade but not 
with alcohol or cirrhosis. Patients with highest level of CD90 expression showed the poorest 
prognosis (Lu et al. 2011). 
In glioma patients, multivariate analysis showed that proportion of CD133+ cells were 
significant to adverse progression-free survival and overall survival. Moreover it was an 
independent risk factor for tumor regrowth and time to malignant progression (Zeppernick et 
al. 2008). In HCC, immunohistochemical analysis also showed that CD133 cells were 
frequently present. Increased CD133 levels were correlated with increased tumour grade, 
advanced diseases stage, and elevated serum alpha-fetoprotein (AFP). Further analysis also 
showed that patients with high CD133 expression was correlated with shorter overall survival 
and higher recurrence compared to patients with low CD133 expression (Song et al. 2008).  
As CD90, in HCC case with and without bile duct tumor thrombi (BDTT), CD133 
expression was closely associated with tumor differentiation. In HCC with BDTT, most of 
these cells were poorly differentiated. This result may indicate that these cells had the 
characteristics of presumed liver cancer stem cells and support the CSCs hypothesis (Yu et al. 
2011). In contrast, Lingala et al. reported that the expression of individual or a combination 
of CSCs markers in HCC is not unique and these markers were also expressed in inflamed or 
nearly normal liver tissues. However, many HCC were positive for ALDH and CD133-
positivity was identified mostly in ADLH+ cells and in nearly two third of specimens. The 
positive rate of CD133 in HCC was similar to viral hepatitis specimens and not all adjacent to 
HCC tissues were positive for CD133, CD90, CD44, and ALDH (Lingala et al. 2010).  
OCT4, an embryonic pluripotency transcription factor, is closely-associated with 
embryonic stage and pre-fetal. It has been found to be expressed in HCC cell lines and HCC 
specimens (Yuan et al. 2010). Furthermore, OCT4 can mediate chemoresistane through a 
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potential OCT4/AKT-ABCG2 pathway and has clinical significance regarding to expression 
patterns in HCC tumors (Wang et al. 2010). In other cancers, OCT4 over-expression was 
found in gastric cancer tissues compared to non cancerous tissues, athropic gastritism and 
gastric ulcer tissues. OCT4 expression was correlated with differentiation status and was 
proposed as one of markers for human gastric cancer (Chen et al. 2009). In rectal cancer, 
together with CD133 and SOX2, OCT4 may be used to predict recurrence and poor prognosis 
after preoperative chemoradioresistance (Saigusa et al. 2009).  
Stem cells identified by immunohistochemical markers using OV-6 and RNA-FISH 
markers using several antibodies including CK19 were found scattered in the liver 
parenchyma of cirrhotic livers and within hepatocellular carcinomas (HCCs). Pre-cirrhotic 
alcoholic or non alcoholic steatohepatitis all stained negative for these stem cells (Oliva et al. 
2010). 
Durnez et al. reported that around 30% of HCC expressed CK7 and/or CK19. These cells 
were potentially derived from malignant degeneration of hepatic progenitor cells. The 
expression of CK7 was significantly associated with hyperbilirubinemia. HCC expressing 
CK19 had a higher incidence of AFP expression, elvated serum AFP, and less advanced liver 
fibrosis. Higher recurrence rate of CK19+ in HCC after transplantation suggested a worse 
prognosis compared to CK19- and might be used as prognostic marker (Durnez et al. 2006).  
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1.5. ABCG2 Expression: Drug Resistance and CSCs 
1.5.1. ABCG2 and drug resistance 
The ATP Binding Cassette (ABC) transporter is one of the largest families of membrane 
transport proteins. These proteins utilize a pair ATP (Adenosine-5'-triphosphate) molecule to 
export specific compounds or to flip them from inner to outer leafs of the membranes 
(Higgins 1992). In humans, there are 49 members of ABC transporters gene which are 
classified into seven subfamilies based on the sequence homology and ATP-binding proteins 
(Dean, Hamon, and Chimini 2001). 
The Breast Cancer Resistance Protein (ABCG2/BCRP/ABCP/MXR) is one member of the 
ATP-Binding Cassette (ABC) transporters superfamily proteins (Dean et al. 2001). ABCG2 
protein is composed of 665 aa resulting a 72 kDa protein. It has an N-terminal ATP-binding 
domain (NBF) and a C-terminal transmembrane domain (TMD), a structure half the size and 
in reverse configuration to most other ABC proteins comprising two NBFs and two TMDs  as 
shown in Figure 1.6 (Doyle & Ross 2003;Robey et al. 2009;Bailey-Dell et al. 2001). The 
ABCG2 gene is highly conserved and has been found in all sequenced vertebrates to date, 
including birds, reptiles, and fish. In most species there is a single gene present (Annilo et al. 
2006). The exceptions to this are the rodents which contain one or more copies of a closely 
related gene, Abcg3; and fish which have 3 or more ABCG2 genes (Mickley et al. 2001).  
 ABCG2 protein is widely expressed in tissues, mainly in placenta, epithelium of small 
intestine and colon, and breast. Furthermore it is also expressed in the epithelium of the 
prostate and bladder, endocervical cells of uterus, kidney tubules and others tissues. In liver, 
ABCG2 is expressed in liver canalicular membrane (Maliepaard et al. 2001) and hepatocytes 
(Fetsch et al. 2006). In the same way, ABCG2 is also found in bile ducts, reactive bile 
ductules, and blood vessel endothelium of human liver (Vander et al. 2006).  
One of the main functions of ABCG2 is related with the cell resistance to exposure of 
external compounds, exporting the drug out of the cells thus maintaining the intracellular 
drug compound below toxic level. Regarding this underlying principle, extensive studies have 
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been carried out to find out the relationship of ABCG2 with drug resistance, especially in 
chemotherapy-treated cancers (Figure 1.6). 
The spectrum of anticancer drugs transported by ABCG2 includes mitoxantrone, 
camptothecin-derived and indolocarbazole topoisomerase I inhibitors, methotrexate and 
flavopiridol (Doyle and Ross 2003). ABCG2 is one of the chemosensitivity determinants of 
irinotecan hydrochloride (CPT-11), an effective anticancer drug (Takahata et al. 2008). 
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Figure 1.6. Physical structure of the ABCG2 gene and promoter. Picture was taken from Doyle 
& Ross 2003 (adapted from Bailey-Dell et al. 2001). 
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In leukemia, ABCG2 may associate with drug resistance and survival (Ross et al. 2000). 
In solid cancers, ABCG2 expression is extensively studied in breast cancer as its first case of 
finding. Its expression is  found to be common in digestive system, lung, and melanoma 
(Diestra et al. 2002).  However, whether its expression increase or decrease in cancers is still 
debatable due to many different reports.  
In resistant cancer cells, ABCG2 expression is associated to many chemotherapy agents. 
In liver cancer cells, treatment of mitoxantrone, doxorubicin, epirubicin, and gefitinib 
resulted in induction of ABCG2 and low sensitivity to the drugs (Cusatis et al. 
2006;Kamiyama et al. 2006;Li et al. 2007). The ABCG2 expression was found to be high in 
hepatocellular carcinoma samples(Sun et al. 2010) and was reported to increase following 
chemotherapy in hepatoblastoma patients  (Vander et al. 2008). 
 
 
 
 
 
 
 
 
 
Figure  1.7. Main function of ABC transporter protein in cell defense mechanism.  One of 
the main roles of ABC transporters including the ABCG2 protein is to export chemotherapies drugs from 
intra- to extracellular compartment and to maintain drug concentration under cytotoxicity level. 
cytoplasm
extracellular space
The ABC transporter protein
drug, conjugates, 
fluorophores, nucleoside 
analogs, etc.
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1.4.2. ABCG2 and side population phenotype 
In 1997, Goodell and colleagues pioneered a technique to purify a small population of 
cells which is rich with stem cells. These cells, more known as side population (SP) 
phenotype, had capacity to export the Hoechst 33342 dye out of the cells and recognized as 
Hoechstnull/low in FACS instrument as shown in Figure 1.7. Hoechst 33342 is a fluorescent dye 
agent binds to double stranded DNA and has been reported to be a substrate of ABCG2. The 
purified SP cells had been obtained from many solid tumors, including isolation of 
stem/progenitor cells from cancer originating from prostate, pancreas, stomach and liver 
(Chiba et al. 2006).  
 
 
 
 
 
 
 
 
Figure 1.8. Side population phenotype of stem cells with Hoechst 33342null/low identified 
by FACS instrument. The SP cells population from hematopoietic stem cells has capacity to pump 
out Hoechst dye out of the cells. This population is rich with stem cells. Sample picture is taken from 
(Bunting 2002). 
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An elegant study from Zhou et al. demonstrated that bone marrow cells from Mdr1a/1b-/- 
mice contained a normal number of SP cells, indicating that Mdr1a/1b is not required for SP 
phenotype. By contrast, a significant reduction of SP cells in bone marrow and skeletal muscle 
was observed in Bcrp1-/- mice, suggesting Bcrp1 as molecular phenotype of SP (Zhou et al. 
2001;Zhou et al. 2002). 
In HCC, the SP population had also been reported. As mentioned previously, the first 
evidence of CSCs existence was found in isolated SP cells of HCC cell lines. Huh-7 SP cells 
were found to be more resistant to anticancer drugs such as doxorubicin, 5-flouracil, and 
gemcitabine, compared to non-SP cells (Haraguchi et al. 2006b;Haraguchi et al. 2006a). The 
SP from cell lines PLC/PRF/5 (0.80%) and HuH7 (0.25%) showed high proliferations, anti-
apoptotic properties and capabilities to initiate tumor formation in non-obese 
diabetes/severe combined immunodeficiency (NOD/SCID) mice (Chiba et al. 2006).  
Moreover, SP cells sorted from HCC cell lines HCCLM3, MHCC97-H, MHCC97-L and Hep3B 
harboured CSCs-like might be related to the metastasic potentials and therapeutic-resistance 
(Shi et al. 2008).  However, this tumorigenesis capacity of ABCG2+ cells is in contrary with a 
report demonstrated that ABCG2+ had similar tumorigenicity to ABCG2- cells in glioma, 
breast, and prostate cancer (Patrawala et al. 2005). 
Further studies on ABCG2 expression in these cell lines showed that the sorted ABCG2+ 
cells generated both ABCG2+ and ABCG2- cells while ABCG2- cells only gave ABCG2- cells, 
indicating higher hierarchy of ABCG2+ compared to ABCG2- cells. Additionally, GATA6, an 
essential factor of earliest phase of hepatic development was intensely expressed in ABCG2+ 
cells and C/EBPβ, a factor for late phase of liver development, was more expressed in ABCG2- 
cells (Zen et al. 2007). A study using drug treatment showed that ABCG2 expression 
significantly influenced the levels of drug efflux. The SP cells were importantly involved in the 
drug efflux-related chemotherapy resistance and the SP analysis was found to be an efficient 
method to evaluate the functional activity of ABCG2 (Hu et al. 2008).  
The relationship between cells differentiation and ABCG2 expression has been also 
reported in previous studies performed in other cells.  High level of functional ABCG2 was 
detected in undifferentiated human embryonic cells and decreased during cellular 
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differentiation (Apati et al. 2008). In hematopoietic system, the ABCG2 expression was 
restricted to the most immature progenitor cells and down-regulated at the committed 
progenitor level (Scharenberg, Harkey, and Torok-Storb 2002). These studies have indicated 
the significance of ABCG2 in human malignancies and its association with drug resistance 
and cells differentiation. 
 
1.4.3. ABCG2 inhibitors 
As mentioned previously, one of the most important appearances of the CSCs is they may 
be resistant to many standard chemotherapies. Tumor relapse often occur and it may spread 
and cause metastasis. The combination of chemotherapy drugs and specific inhibitors 
targeting ABC transporters, including ABCG2, could be a potential strategy to eliminate both 
tumor cells and the CSCs (Dean et al. 2005).   
Bench and clinical studies focus on increasing the sensitivity of cancer cells to anticancer 
drugs is ongoing. Some strategies include the specific drug delivery system, transporters 
inhibitors and targeted antibodies. The use liposome-encapsulated adriamycin through 
hepatic arterial administration improve the anticancer efficacies in hepatoma compared to 
adriamycin solution alone  (Sun et al. 2006). Recent studies proposed also the use of nucleic 
acid constructs on ABC transporters gene to be efficient and safe system.  Adenoviral delivery 
of the ABCC2 antisense sequence reduced the inhibitory concentration (IC50) for 
doxorubicin, vincristine, cisplatin and etoposide in HepG2 cell line. A significant tumor 
regression was also observed in nude mice after vincristine treatment  (Folmer et al. 2007). 
Combination between modulators and antibody against transporters protein has been 
performed as another approach (Goda et al. 2007). 
 Many inhibitors have been attempted in clinical studies against ABCB1 including 
competitive inhibitors verapamil and cyclosporine A (the first and second generation), and 
blocker GF120918 (third generation). ABCB1 modulators cyclosporine analog PSC 833, 
GG918 and verapamil was reported improve hepatoblastoma response to doxorubicin in vitro 
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(Warmann et al. 2002). A clinical trial of biricodar (VX-710), a ABCB1 and ABCC1 inhibitor, 
is reported sensitize antracycline-resistant sarcoma to doxorubicin (Bramwell et al. 2002). 
A high throughput cell-based screen for ABCG2 has been established and is being used to 
identify new inhibitors  (Henrich et al. 2006). Fumitremorgin C (FTC) and Kol43 are potent 
inhibitors of ABCG2. FTC at 5 µM concentration almost completely reversed resistance 
mediated by ABCG2 to mitoxantrone, doxorubicin and topotecan (Doyle and Ross 2003). 
Kol43, the tetracyclic analog of FTC, is a specific ABCG2 inhibitor without the neurotoxicity 
that is a principal side effect of FTC (Allen et al. 2002). Novobiocin, a coumermycin 
antibiotic, is reported to effectively overcome ABCG2-mediated drug resistance (Yoshikawa et 
al. 2004). GF120918, a ABCB1 inhibitor, is reported to be less specific than FTC but without 
neurotoxicity impact, increases drug accumulation and cytotoxicity in cells expressing ABCG2 
(de et al. 1999). A natural substrate naringenin, a flavonoid in grapefruit juice, showed also 
an anti-ABCG2 effect. The addition of naringenin increased the chemosensitivity and 
intracellular accumulation of drugs CPT-11 and SN-38 in HCC cells expressing abundant 
ABCG2 (Takahata et al. 2008).   
Nevertheless, serious toxicity of those inhibitors to the cells needed a careful inspection. 
Some considerations should also be taken on drug sensitization, biochemical 
characterization, and transport studies (Henrich et al. 2006). Combination regiments therapy 
containing low concentration of anticancer drugs and inhibitors with a better targeting 
system will be useful for the successful of the therapy. A report of combined application of 
UIC2 monoclonal antibody and certain ABCB1 modulators including cyclosporine resulted in 
a completely restored steady-state accumulation of various Pgp substrates and inhibited the 
pump activity almost completely. The low concentration of modulators to approximately 20 
times significantly decreased cytotoxicity (Goda et al. 2007).  
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The cancer stem cells (CSCs) theory as cancer initiation models had been proposed by 
many studies. Evidences of tumor initiating cells had been demonstrated both in circulating 
and solid cancers. These cells have the specific capacity just as normal stem cells to proliferate 
and differentiate into other cells, but more importantly, a unique ability to promote and 
invade tumor in animal model. 
Primary liver cancer, one of the most fatal cancers in the world, is caused by various 
known risk factors. Besides extrinsic factors, intrinsic individual variations may present wide 
disease characteristic, subtypes, and prognostic significances.  Morphologically, liver is 
consisted of many types of cells and during its development, liver organogenesis takes place 
by joint coordination between endoderm and mesoderm layers. Furthermore, 
hepatocarcinogenesis is also a process of interaction between cancer cells and cancer 
microenvironment, a state that provides supportive niche for cancer growth and invasion. 
Regarding treatment strategy of liver cancer, low response of cancer cells to the 
conventional treatment has been an important issue in cancer biology and biomedicine. 
Whereas surgical treatment is considered as the best choice for patients with early disease, 
chemotherapy is given to eliminate cancer cells and avoid metastasis in unresectable patients 
with higher stages of disease.  However, survival of this group has not significantly increased 
in several decades. Chemoresistance plays role to therapy failure and relates with the 
presence of CSCs. 
The main objective of this thesis is study the cells heterogeneity in hepatic system to have 
a comprehensive outlook of hepatic CSCs theory. It is pathologically and clinically important 
to gain more information in the heterogeneity of liver cancer cells, the distribution of stem 
cells in the liver, and whether there is an association between stem cells or CSCs and drug 
resistance in liver cancer. 
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Main objective is specified into three inter-related projects with several experimental 
models, both in vivo and in vitro.  The first task is to isolate and characterize a population 
with stem cells characteristic from tumoral and distal parts of human primary liver cancers 
hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Second task is to assess the 
expression of several stem cells markers in transcriptional level in clinical samples tissues.  
And the third task is to study the expression of a drug transporter ABCG2 in relation with 
cells differentiation and drug resistance. Further explanation of these tasks are described in 
the chapter Results and General Discussion.  
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IHH HepG2 HuH-7 JHH-6
differentiation
3.1.   Materials 
3.1.1. In vitro models: hepatic cell lines 
Human liver cell lines IHH, HepG2, HuH-7, and JHH6 were used as in vitro models. The 
immortalized non tumoral liver cells IHH was a kindly provided from Dr. Didier Trono (Mai 
et al. 2005). Human HCC cell lines HuH-7 (JCRB0403) and JHH-6 (JCRB1030) were 
obtained from the Japan Health Science Research Resources Bank (HSRRB, Tokyo, Japan). 
The HepG2 cell line was obtained from the Istituto Zooprofilattico Sperimentale della 
Lombardia e dell’Emilia Romagna (IZSLER, Brescia, Italy). The morphology of the cell lines 
used in this study was shown in Figure 3.1.  
The IHH cells were grown in DMEM-F12 medium supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS), 1% antibiotics, 1% L-glutamine, 1 uM dexamethasone 
and 5 ug/mL insulin. The HepG2 and HuH-7 cells were grown in DMEM medium (high 
glucose) supplemented with 10% (v/v) heat-inactivated FBS, 1% L-glutamine and 1% 
antibiotics. The JHH6 cells were grown in Williams’ E medium supplemented with 10% (v/v) 
heat-inactivated FBS, 1% L-glutamine and 1% antibiotics. The cultures were maintained at 
37°C in a humidified 5% CO2 incubator and were routinely passaged with 0.05% Trypsin in 
PBS when they reached 85% - 95% confluence. 
 
 
 
Figure 3.1. Morphology of hepatic cell lines for study in vitro. Cell lines IHH, HepG2, HuH-7, 
and JHH-6 with different degree of morphologic differentiations were used as models. Magnification 
100x. 
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3.1.2. Human primary liver cells 
Fresh liver tissues as the sources of primary cells cultures from 11 patients undergoing 
liver surgery were obtained from Surgical Department, Hospital of Cattinara, Trieste in 
period June 2008 – September 2010. Informed consent was obtained from each patient 
before surgery. Six patients were diagnosed with HCC, three with CC, one with cystic hepatic, 
and one with steatosis and not confirmed as HCC. Female and male ratio is 6:5 with age mean 
70 ± 9 years old (range 54 – 81 years old) and three samples were HCV positive. From those 
tissues, three parts were selected: the neoplastic (tumoral), peripheral (peritumoral), and 
distal (‘normal’) region. 
 
3.1.3. Clinical samples: human liver tissues 
A total of 59 human liver tissues were obtained from patients undergoing liver resections 
or liver transplantations. Several liver pathologies included hepatocellular carcinoma (HCC), 
cholangiocarcinoma (CC), biliary atresia (BA), hepatoblastoma (HB) and normal donor 
tissues as control. Most of those included the tumoral, peripheral, and non-tumoral regions. 
All tissues were snap-frozen in liquid nitrogen and stored in -80°C before processing.  
 
3.1.4. Xenotransplantation animals 
Athymic nude Foxn1(nu/nu) homozygotes mice for in vivo xenotransplantation studies 
were bought from Harland Laboratories, SRL (Udine, Italy). The mice were 7 weeks age, male 
and maintained in animal house facility University of Trieste. Xenotransplantation study was 
approved by Ministero della Salute, Direzione Generale della Sanità Animale e del Farmaco 
Veterinario, no. 107/2010 – B (07 June 2010).  
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Figure 3.2. Work flow of general methods. Collaborative approaches using both in vivo and in vitro sample models and cellular and 
molecular biology techniques were performed for three objectives of the study: identification of stem cells in the PLCs, expression of stem 
cells markers in tissues samples, and ABCG2 study. 
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3.2.   Methods 
3.2.1. General techniques 
Fluorescence activated cells sorting (FACS) 
The presence of surface marker antigens in the cell lines and primary cultures were 
detected by FACS. The cells were detached from the wells by a short treatment with trypsin–
EDTA and placed in centrifuge tubes. After centrifugation at 1000 rpm for 5 minute at room 
temperature, the supernatant was discarded and the pellet was washed two times with sterile 
phosphate buffer saline (PBS) with 0.5% bovine serum albumin (BSA) (w/v) and filtered with 
40 µM cell strainer (BD BioScience). At least 2 x 106 cells/mL cells were incubated with 
specific first antibodies for 30-60 minutes on ice in the dark. After two PBS-0.5% BSA 
washes, if necessary, the cells were incubated with secondary antibody for 30-60 minutes on 
ice in the dark. Flow cytometric analysis was performed immediately on a FACSCalibur flow 
cytometer (Becton Dickinson, NJ, USA). A total of 10,000 events were analyzed per sample. 
Nonspecific staining for secondary antibody was assessed.  
Cells separation of JHH-6 by magnetic sorting 
CD90+ cells positive selection of HCC cell line JHH6 was performed by indirect method 
using magnetic cell sorting (Miltenyi Biotec GmbH, Germany). A total of 20 millions cells 
were detached from cell culture flasks by treatment with trypsin–EDTA and placed in 
centrifuge tubes. After filtration with 40 µm cell strainer, the cells were suspended in 200 µL 
of prepared buffer (PBS pH 7.2, 0.5% BSA, 2 mM EDTA) with 20 µL CD90-FITC (10 µL first 
antibody in 10 millions of cells) and were incubated for 10 minutes on ice in the dark. After 
two washes 1000 rpm, 10 minutes, 4°C, the cells were re-suspended in 180 µL of buffer and 
20 µL anti-FITC microbeads (Cat.no. 130-048-701, Miltenyi Biotec GmbH, Germany) and 
incubated for 15 minutes on ice. After washing, the cells were re-suspended in 500 µL buffer 
and proceed to magnetic separation. 
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The cells were passed in MS column of a magnetic field separator with three washings, 
the labeled cells remained in the column and unlabeled cells passed through in collection 
tube. Immediately, positive fraction were removed from the magnetic field and collected in 
separate tube. This procedure might be conducted for three times until separation purity was 
reached. After sorting, the cells were washed and plated back in the presence of antibiotics. 
The success of cells separation was directly checked by FACS. 
Protein extraction 
For total protein extraction, cells were dissolved in cell lysis buffer (PBS containing 1% 
v/v of a protease inhibitor cocktail [Sigma, P8340] and 2 mM phenyl-
methylsulfonylfluoride). Cells were then placed on ice for 10 minutes and disrupted by 
scrapping and pipetting. Protein lysate were obtained by centrifugation at 14,000 rpm for 10 
minutes in 4°C.  
The protocol for membrane protein purification was based on Paulusma method 
(Paulusma et al. 1999). Cells were lysed and scraped in ice-cold 2 mM EDTA and 200 µM 
PMSF in PBS and then centrifugated  for 5 minutes at 1000 g in 4°C. Cells pellet was 
dissolved in 1 mM bicarbonate and kept in ice for 30 minutes and then subsequently 
homogenized in a glass potter (tight pestle, 50 times) in ice and centrifugated for 8 minutes at 
1000 g in 4°C. The supernatant was centrifugated for 1 hour at 100,000 g in 4°C and the 
resulted pellet was dissolved in 250 mM sucrose/10 mM Hepes/Tris pH 7.4 and re-
homogenized using glass potter. Total protein extract was stored in -80°C and membrane 
protein in liquid nitrogen. Protein concentration was determined by copper (II) sulphate 
solution (Sigma-Aldrich, C2284) and bicinchonic acid ((Sigma, B9643) protein assay 
following the manufacturer’s instructions.  
Western Blot 
Proteins of desired quantity (in µg) were size-separated, together with molecular weight 
standards (Fermentas, SM1811), by (SDS–PAGE) on 10% polyacrylamide gel, using a Mini 
Protein III Cell (Bio-Rad, Hercules, CA, USA). After SDS–PAGE, proteins were electro-
transferred with a semi-dry blotting system at 100V for 90 min onto immune-blot PVDF 
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membranes (Bio-Rad) using a Mini Trans-Blot Cell (Bio-Rad). Membrane was incubated 
overnight at 4°C with first antibody at dilution 1:50 to 1:1000 in 4% skim milk or BSA in T-
TBS buffer (Tris 20 mM, Tween 20, 0.2%, NaCl 500 nM, pH 7.5). After three washes with T-
TBS the membranes were incubated with secondary antibodies with peroxidase conjugate at 
dilution 1:1000  to 1:4000 in 4% skim milk or BSA in T-TBS for 1 hour in room temperature. 
The peroxidase reaction was obtained by exposure of membrane in the ECL-Plus Western 
blot detection system solutions (ECL Plus Western blotting Detection Reagents, GE-
Healthcare Bio-Sciences, Italia).  
Total RNA isolation 
Total RNA from the cell lines and tissues was extracted using the TriReagent solution 
according to the manufacture’s protocol (T9424, Sigma–Aldrich, Milan, Italy). The cells on 25 
cm2 culture flask were grown until they reached ~85% confluence. The cells were washed two 
times with PBS and lysed with 1 mL of TriReagent. After scrapping and pipetting, the lysate 
was removed to a microtube and homogenized by vortexing. After addition of 200 µL 
chloroform per 1 mL TriReagent, the tube was centrifuged at 12,000 rpm for 15 minutes at 
4°C and the upper layer containing RNA was removed to a new microtube. For RNA 
precipitation, 500 µL isopropanol per 1 mL TriReagent was added. The tube was centrifuged 
at 12,000 rpm for 10 minutes at 4°C and the supernatant was discarded. The RNA pellet was 
washed with 1 mL of cold ethanol 75% and centrifuged at 8,000 rpm for 5 minutes at 4°C. 
After air-drying for 15 minutes, the pellet was diluted in 10 – 50 µL of sterile water. 
Total RNA samples were quantified in a spectrophotometer at 260 nm. Absorbance ratio 
at 260/280 nm and 260/230 nm was used to asses the purity of the samples. Agarose gel 
electrophoresis and staining with ethidium bromide, indicated that the RNA preparations 
were of high integrity.  
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Reverse transcription (RT) and real time quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) 
The RT using 1 ug of total RNA was performed with an iScript cDNA synthesis Kit (170–
8891, Bio-Rad) according to the manufacture’s suggestions. A total of 20 uL volume reaction 
was conducted in a thermocycler (Gene Amp PCR System 2400, Perkin-Elmer, Boston, MA, 
USA) at 25 °C for 5 min, 42 °C for 45 min, 85 °C for 5 min. The final cDNA was conserved at -
20 °C until used. 
The qRT-PCR was performed according to the iQ SYBR Green Supermix (Bio-Rad) 
protocol. PCR amplification was carried out in 15 uL reaction volume containing 25 ng of 
cDNA, 1x iQ SYBR Green Supermix containing 100 mM KCL; 40 mM Tris–HCl; pH: 8.4; 0.4 
mM each dNTP; 50 U/mL iTaq DNA polymerase; 6 mM MgCl2; SYBR Green I; 20 mM 
fluorescein; and stabilizers (Bio-Rad Laboratories) and 250 nM gene specific sense and anti-
sense primers. Reactions were run and analyzed on a Bio-Rad iCycler iQ real-time PCR 
detection system (iCycler  IQ5 software, version 3.1; Bio-Rad) together with reference genes. 
Cycling parameters were determined and analyzed using the Pfaffl modification of the ∆∆Ct 
equation with taking accounts to the efficiency of the reaction (Pfaffl 2001).  
Primer design 
The primers for qRT-PCR were designed using software Beacon Designer Version 7.9 
(Premier Biosoft International, Palo Alto, CA, USA). Primer sets were built across two exons 
to avoid contamination of genomic DNA. Nucleotide BLAST was performed to check the 
specificity of the sequences. Melting curve analysis and agarose gel electrophoresis were 
carried out to asses templates products. The list of the primers description and sequences 
were shown in Table 3.2 and Table 3.3. 
Statistical analysis  
Box plot graphics and statistical analysis were constructed using software SigmaPlot 
Version 11.0 (Systat Software, Inc., Chicago, USA).  The student’s t-test was performed for 
statistical comparison between groups. Value of p<0.05 was regarded as statistically 
significant. 
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3.2.2. Identification of stem cells from human liver tissues 
Primary cell cultures  
The primary cell cultures of human liver were obtained from patients undergoing partial 
hepatic resection. Directly from the hospital, the tissues were kept in a falcon tube without 
any buffers and keep it in ice for maximum 3 hours before processing. 
Under the sterile hood, the tissue (about 1 cm3 in size) was washed twice with pre-
warmed PBS. After the tissue was cut into small pieces using blade and scalpel and 
dissociated using collagenase type 4 (C5138, Sigma) for 5-15 minutes in a CO2 incubator 37°C, 
95% humidity, 5% CO2. The enzyme activity was blocked with a minimum an equal volume of 
PBS + 10% FBS. After centrifugation (1,800 rpm, RT, 5 minutes) they were washed twice with 
pre-warmed PBS and filtered through a 40 µm cell strainer gradually several times. The flow 
through and the remain pellets on the filter were again washed and plated on 100 mm dishes 
in MyeloCult® medium (StemCell Tech., Vancouver, BC, Canada) in the presence of 10-6 M 
hydrocortisone sodium succinate and 1% of antibiotics. The cells were grown in a CO2 
incubator: 37°C, 95% humidity, 5% CO2 with media changes every 3-4 days.  
Characterization of stem cells 
The surface markers of isolated cancer stem cells were checked by FACS using antibodies 
CD90, CD133, CD45, and CD44 (Table 3.1). Wider analysis to characterize the primary cells 
was done by real time RT-PCR. The detail of procedure and methods for FACS and RT-PCR 
were explained in previous subchapters. The expression of genes studied including: Cluster of 
Differentiation (CD) CD90, CD133, CD117 (c-kit), CD34, CD45, CD29, CD31, CD105, and 
CD166; marker for hepatocytes and epithelial biliary albumin, cytokeratin 7 (CK7) and 
cytokeratin 19 (CK19); pluripotency markers OCT4 and SOX2; ABC transporter 
ABCG2/BCRP. The description of genes identification is listed in Table 3.2 and Table 3.3. 
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The Colony Forming Unit – Fibroblast (CFU-F) assay 
The isolated cells from passage °1 – passage °6 were plated in low density on 25 cm2 flask 
for 4 weeks. After two washing with PBS, the cells were fixed by cold methanol for 10 minutes. 
The staining was done with Wright-Giemsa staining solution (WG16, Sigma) for 10 minutes. 
The CFU-F colonies were identified macroscopically and microscopically under light 
microscope.  
Differentiation to adipocytes 
The primary cultures were plated on 35 mm tissue culture dishes with 1.5 mL of 
AdipoDiff medium (130-091-677, Miltenyi Biotec). The medium was changed each 4 days and 
the cells were maintained for 2 – 3 weeks in culture. The identification of adipocytes was 
performed by qRT-PCR on gene PPARG (peroxisome proliferator-activated receptor gamma), 
master regulation of adipocytes differentiation (Table 3.3. and Table 3.4). Fat deposits in the 
cytoplasm were stained using Nile Red, a particular intercellular lipid staining. Cells on 
coverslip were washed and fixed with methanol for 15 minutes. After two times washing, cell 
nucleus was stained with Hoechst 33328 for 10 minutes at room temperature. Nile Red (1:50 
in acetone) was added and the plate was gently shaken on a plate shaker for 20 minutes. 
Immediately after washing with de-ionized water, cells were examined under fluorescence 
microscope.  
Differentiation to pancreatic cells 
The protocol for pancreatic cells differentiation was performed according previous 
reports (Yang et al. 2002;Herrera et al. 2006). Briefly,  primary cultures were plated on 35 
mm tissue culture dishes with 3 mL DMEM-HG medium supplemented with 10% FBS, 1% 
antibiotics and 1% L-glutamine. After 7 days of plating, 10 mM of nicotinamide (N0636, 
Sigma) was added and medium was routinely changed for 2-3 days and cells were maintained 
until 3 weeks. The identification of cells was performed by qRT-PCR on genes GIP and 
somatostatin (Table 3.3 and Table 3.4). 
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Xenograft assay: pilot study 
The capacity of isolated stem cells from human liver tissues to induce tumor in model in 
vivo in male nude mice Foxn1(nu/nu) age 7 – 10 weeks old was performed and currently is 
under evaluation. Briefly, single cells suspension was prepared using trypsin-EDTA 
detachment from several 75 cm2 cell culture flasks. After washing, the cells were counted 
using a counting chamber to reach a desired concentration. After centrifugation 1000 rpm, 
4°C for 5 minutes, cells pellet was re-suspended in 400 µL cold PBS and placed in ice. The 
injection was injected subcutaneously into left and right abdomen of the mouse. Duplicates 
were performed in the same mouse. Viability of the cells was checked by tryphan blue staining 
dye. The xenotransplantated mice together with control were observed for four months after 
injection. Mouse body weight was measured every week. 
 
3.2.3. Expression of stem cells markers in human liver tissues  
The gene expression study of several markers in human liver tissues was performed using 
qRT-PCR. The following genes were studied: stem cells surface markers CD90, CD133 and 
EpCAM, pluripotency markers OCT4, and cytokeratin 7 and cytokeratin 19. The target genes 
mRNA expressions were normalized to reference genes 18S-rRNA, β-actin, and GAPDH. The 
description of primers is listed in Table 3.2. Box plot graphics and statistical analysis were 
constructed using software SigmaPlot Version 11.0 (Systat Software, Inc., Chicago, USA). 
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3.2.4. ABCG2 expression: drug resistance and CSCs 
In vitro drug cytotoxicity test 
The cytotoxic effects of doxorubicin hydrochloride (D1515, Sigma-Aldrich), verapamil 
hydrochloride (V4629, Sigma-Aldrich) and Hoechst 33342 (B2261, Sigma-Aldrich) were 
assessed by 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT; 
M2128, Sigma-Aldrich) dye reduction test. The cells were seeded in concentration 20,000 
cells/cm2 in 24-well plates for corresponding time. The dose ranges of doxorubicin, verapamil 
and Hoechst used in this study were 0.0 – 10.0 µM, 0.0 – 20 µM and 0.0 – 50 µg/mL, 
respectively. For doxorubicin the exposure time is 24 hours whereas for verapamil and 
Hoechst, exposure time of the compounds was tested on 30, 90 and 270 minutes as required 
time for Hoechst exclusion assay.  
Briefly, when MTT  was taken up by living cells, it was converted from a yellow to a water 
insoluble blue-colored precipitate by cellular dehydrogenases (Mosmann 1983). After 
treatment, the medium was removed and the treatment was followed by addition of 0.5 
mg/mL of MTT and incubation for 1 h at 37°C. The cells were then lysed and the resulting 
blue formazan crystals were solved in DMSO. The absorbance of each well was read on a 
microplate reader (Beckman Coulter LD 400C Luminescence detector) at 562 nm. The 
absorbance of the untreated controls was taken as 100% survival. The data represented the 
mean ± SD of three independent experiments. 
ABCG2 mRNA expression 
The ABCG2 mRNA expression was studied both in clinical samples and cell lines in the 
basal condition and after exposure to 5 µM doxorubicin for 24 hours. The ABCG2 mRNA 
expression was normalized to reference genes 18S-rRNA, β-actin, and GAPDH. The details of 
total RNA extraction and real time RT-PCR had described in previous subchapters. 
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Protein expression 
For ABCG2 protein expression, membrane protein fractions were purified from basal 
condition and after exposure to 5 µM doxorubicin on hepatic cell lines IHH, HuH-7, and 
JHH-6. A total of 30 µg membrane protein was subjected to Western Blot. ABCG2 antibodies 
used in this experiment is anti-BCRP  BXP-53 (Ab24115, abcam), dilution 1:200, with second 
antibody anti-rat IgG peroxidase (A5795, Sigma) dilution 1:1000, resulted protein band with 
molecular weight 72 kDa. As control, housekeeping protein actin was also checked with 
antibodies anti-actin (A2066, Sigma), dilution 1:1000 with second antibody anti-rabbit IgG 
peroxidase (P0448, Dak0) dilution 1:2000, resulted protein band 42 kDa. Details of Western 
Blot procedure was described in previous subchapter.  
Hoechst 33342 efflux assay 
The activity of ABCG2 in cell lines HepG2, HuH-7 and JHH-6 was assessed using 
Hoechst 33342 efflux assay with modification from previous report (Plumb, Milroy, and Kaye 
1990). Single cells suspension was filtered with 40 µm cells strainer (BD Falcon). Sterile 1 µM 
or 20 µM final concentration of verapamil hydrochloride (V4629, Sigma-Aldrich) were added 
and the cells were incubated for 30 minutes in 37°C. After incubation, 5 µg/mL Hoechst 
33342 (B2261, Sigma-Aldrich) was added and the cells were incubated for 90 minutes in 
37°C. Subsequently, the reaction was stopped by incubating the cells on ice for 5 minutes. The 
Hoechst 33342 efflux was measured by spectrofluorometer (Jasco FP-770, Maryland, USA) 
on 355 nm excitation and 460 nm emission wavelength. 
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Table 3.1. List of antibodies for protein identification 
Markers  Clone Cat. No.  Company Applications  
First antibody     
CD90-FITC 5E10 #10427 StemCell Tech. FACS, cell sorting, 
Immunofluorescence 
CD44 F10-44-2 Ab6124 Abcam FACS, Immunofluorescence 
CD133  AC133 130-090-422 Miltenyi Biotec FACS 
CD117 AC126 130-091-735 BD Biosciences FACS 
CD34 My10 348050 BD Biosciences FACS 
CD45-PE 5B1 130-080-202 Miltenyi Biotec FACS 
CD90 5E10 14-0909 eBioScience Western Blot 
ABCG2/BCRP BXP53 Ab24115 Abcam  Western Blot 
Actin   A2066  Sigma Western Blot 
Secondary antibody     
Anti-mouse-FITC  715-096-150 Jackson ImmunoResearch FACS, IF 
Anti-mouse IgG  P0260 Dako Western Blot 
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Anti-rat IgG HRP  A5795 Sigma Western Blot 
Anti-rabbit IgG  HRP  P0448 Dako Western Blot 
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Table 3.2. List of the genes for the identification of isolated cells populations 
Gene Official name Alias Function 
Reference genes 
18S 18S ribosomal RNA RN18S1 rDNA repeating units 
GAPDH glyceraldehyde-3-phosphate 
dehydrogenase 
G3PD; GAPD; MGC88685 catalyzed an important energy-yielding step in 
carbohydrate metabolism 
ACTB actin, beta PS1TP5BP1 involved in cell motility, structure, and integrity 
Cell surface markers 
CD90 Thy-1 cell surface antigen FLJ33325; THY1 adhesion molecules', found in stem cells 
CD133 prominin 1 RP41; AC133; MCDR2; 
STGD4; CORD12; PROML1; 
MSTP061; PROM1 
often expressed on adult stem cells, where it is 
thought to function in maintaining stem cell 
properties by suppressing differentiation 
CD117 v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene 
homolog 
PBT; SCFR; C-Kit; KIT a type 3 transmembrane receptor for MGF (mast 
cell growth factor, also known as stem cell factor) 
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CD29 integrin, beta 1 (fibronectin 
receptor, beta polypeptide, 
antigen CD29 includes MDF2, 
MSK12) 
FNRB; MDF2; VLAB; GPIIA; 
MSK12; VLA-BETA; ITGB1 
involved in cell adhesion and recognition in a 
variety of processes  
CD31 platelet/endothelial cell 
adhesion molecule 
PECAM-1; FLJ58394; 
PECAM1 
platelet/endothelial cell adhesion molecule 
CD34  CD34 molecule  selectively expressed on human hematopoietic 
progenitor cells 
CD44 CD44 molecule (Indian blood 
group) 
IN; LHR; MC56; MDU2; 
MDU3; MIC4; Pgp1; 
CDW44; CSPG8; HCELL; 
MUTCH-I; ECMR-III; 
MGC10468 
cell-surface glycoprotein involved in cell-cell 
interactions, cell adhesion and migration 
CD45 protein tyrosine phosphatase, 
receptor type, C  
LCA; LY5; B220; T200; 
CD45R; GP180; PTPRC 
regulate a variety of cellular processes including cell 
growth, differentiation, mitotic cycle, and oncogenic 
transformation. This gene is specifically expressed 
in hematopoietic cells.  
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CD105 Endoglin  END; ORW; HHT1; ORW1; 
FLJ41744; ENG 
a major glycoprotein of the vascular endothelium. a 
component of the transforming growth factor beta 
receptor complex and it binds TGFB1 and TGFB3 
with high affinity.  
CD166 activated leukocyte cell 
adhesion molecule 
MEMD; FLJ38514; 
MGC71733; ALCAM 
activated leukocyte cell adhesion molecule 
EpCAM epithelial cell adhesion 
molecule 
EGP; ESA; KSA; M4S1; MK-
1; EGP-2; EGP34; EGP40; 
KS1/4; MIC18; TROP1; CO-
17A; Ep-CAM; hEGP-2; 
CO17-1A; GA733-2; TACST-1; 
TACSTD1; 
is expressed on most normal epithelial cells and 
gastrointestinal carcinomas and functions as a 
homotypic calcium-independent cell adhesion 
molecule.  
Hepatic and biliary markers 
Albumin Albumin  PRO0883; PRO0903; PRO1341; 
DKFZp779N1935 
a soluble, monomeric protein synthesized in the 
liver which comprises about one-half of the blood 
serum protein.  
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AFP alpha-fetoprotein FETA; HPAFP a major plasma protein produced by the yolk sac 
and the liver during fetal life. Alpha-fetoprotein 
expression in adults is often associated with 
hepatoma or teratoma 
CK19 keratin 19 K19; K1CS; MGC15366; KRT19 intermediate filament proteins responsible for the 
structural integrity of epithelial cells 
CK7 keratin 7 K7; SCL; K2C7; MGC3625; 
MGC129731; KRT7 
is specifically expressed in the simple epithelia 
lining the cavities of the internal organs and in the 
gland ducts and blood vessels. 
ABC transporter gene 
ABCG2 ATP-binding cassette, sub-
family G (WHITE), 
member 2 
MRX; MXR; ABCP; BMDP; MXR1; 
ABC15; BCRP1; CD338; CDw338; 
EST157481; MGC102821; BCRP 
function as a xenobiotic transporter which may 
play a major role in multi-drug resistance.  
Pluripotency markers 
OCT4 POU class 5 homeobox 1 OCT3; OTF3; OTF4; MGC22487; 
POU5F1 
is associated with self-renewal in embryonic 
stem cells 
SOX2 SRY (sex determining 
region Y)-box 2 
ANOP3; MCOPS3; MGC2413 a transcription factor involved in the regulation 
of embryonic development 
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Table 3.3. List of primer sequences for the identification of isolated cells 
Gene Acc. No. Length Sequence F Sequence R exons Size 
(bp) 
position Reference 
18S NR_003286.2 1869 TAACCCGTTGAACCCC
ATT 
CCATCCAATCGGTAGTAG
CG 
1 150 1578 - 
1727 
(Schmittgen and 
Zakrajsek 2000) 
GAPDH NM_002046.3 1310 CCCATGTTCGTCATGG
GTGT 
TGGTCATGAGTCCTTCCA
CGATA 
4 145 460 - 
604 
(Yoshida et al. 
2001) 
ACTB NM_001101.3 1852 CGCCGCCAGCTCACCA
TG 
CACGATGGAGGGGAAGA
CGG 
1 - 2 120 70 - 189 CSF 
CD90 NM_006288.2 1791 AGAGACTTGGATGAG
GAG 
CTGAGAATGCTGGAGAT
G 
4 178 1338 - 
1515 
CSF 
CD133 NM_006017 3794 CATCTGCTCTCTGCTG
AC 
AACTTAATCCAACTCCAA
CC 
13 – 15  152 1532 - 
1683 
CSF 
CD117 NM_000222 5190 AGGCTCTTCTCAACCA
TCTG 
ATTCATTCTGCTTATTCTC
ATTCG 
1 – 2 179 153 - 331 CSF 
CD29 NM_002211.3 3879 GCCTTGGTGTCTGTG
CTGAG 
AGTCGTCAACATCCTTCT
CCTTAC 
14 - 15 189 2128 - 
2316 
CSF 
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CD31 NM_000442 3754 GAGTCCAGCCGCATA
TCC 
TGACACAATCGTATCTTC
CTTC 
6 183 1132 - 
1314 
CSF 
CD34 NM_00102510
9  
2621 CTGATACCGAATTGTG
ACTC 
TTGGGCGTAAGAGATGTC 9 120 1400 - 
1519 
CSF 
CD44 NM_000610 5748 CTCATACCAGCCATCC
AATG 
GAGTCCATATCCATCCTT
CTTC 
10 – 11  133 1726 - 
1858 
CSF 
CD45 NM_002838.3 5330 CGGCTGACTTCCAGAT
ATGAC 
GCAGTGGTGTGAGTAGG
TAAG 
2 - 5 183 159 - 341  CSF 
CD105 NM_001114753
.1 
3072 CTTCCTCCTCCACTTC
TAC 
GGACTTCCTGGTCTTGAG 13 - 14 101 2006- 
2106  
CSF 
CD166 NM_001627.2 4760 GAAGGAGGAGGAATA
TGGAATC 
GTCAAGTCGGCAAGGTAT
G 
1 - 2 152 527 - 678 CSF 
EPCAM NM_002354.1 1731 GAATAATAATCGTCAA
TGCCAGTG 
CGCTCTCATCGCAGTCAG 2 - 3 188 478 - 665 CSF 
Albumin NM_000477.3 2215 GGCATCCTGATTACTC
TGTCG 
AATTCTGAGGCTCTTCCA
CAAG 
9 - 10 150 1121 - 
1270  
CSF 
AFP NM_001134 2032 GCGGCTGACATTATTA TTGGCACAGATCCTTATG 11 - 12 192 1473 - CSF 
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TCG G 1664  
CK19 NM_002276.4 1490 TGAGTGACATGCGAA
GCCAATAT 
GCGACCTCCCGGTTCAAT 4 - 5 103 888 - 
990 
(Dimmler et al. 
2001) 
CK7 NM_005556.3 1753 TGAATGATGAGATCA
ACTTCCTCAG 
TGTCGGAGATCTGGGACT
GC 
4-5 76 750 - 855 (Dimmler et al. 
2001) 
ABCG2  NM_004827    4445 TATAGCTCAGATCATT
GTCACAGTC 
GTTGGTCGTCAGGAAGA
AGAG 
9 - 10 124 1389-
1512 
CSF 
OCT4 NM_002701 1411 AGCGAACCAGTATCG
AGAAC 
TTACAGAACCACACTCGG
AC 
3 - 4 142 752 - 893 (Park et al. 
2008) 
SOX2 NM_003106.2 2518 AGCTACAGCATGATG
CAGGA 
GGTCATGGAGTTGTACTG
CA 
1 126 935 – 
1060 
(Park et al. 
2008) 
PPARG NM_138712.3 1892 ACGAAGACATTCCATT
CACAAG 
TCTCCACAGACACGACAT
TC 
7 - 8 199 396 - 594 CSF 
GIP  NM_004123.2 711 CCCTCAACCTCGAGGC
CCCA 
CCCGAGCCTCCCTCTGGG
TG 
3 - 4 161 230-390 CSF 
SST NM_001048.3 665 CCCAGACTCCGTCAGT
TTCT 
AGCCTGGGACAGATCTTC
AG 
1 - 2 144 207 - 350 CSF 
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Table 3.4. List of the genes for the identification of cells-directed differentiation to adipocytes and pancreatic cells 
Markers Gene Official name Alias Function 
Adipocytes 
differentiation 
PPARG peroxisome 
proliferator-activated 
receptor gamma 
GLM1; CIMT1; 
NR1C3; PPARG1; 
PPARG2; 
PPARgamma 
The protein encoded by this gene is PPAR-gamma 
and is a regulator of adipocyte differentiation.  
Pancreatic 
differentiation 
GIP gastric inhibitory 
polypeptide 
- It encodes an incretin hormone and belongs to the 
glucagon superfamily. It maintains glucose 
homeostasis as it is a potent stimulator of insulin 
secretion from pancreatic beta-cells following food 
ingestion and nutrient absorption.  
 SST somatostatin SMST This hormone is an important regulator of the 
endocrine system through its interactions with 
pituitary growth hormone, thyroid stimulating 
hormone, and most hormones of the gastrointestinal 
tract. 
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4.1. Primary Cells  
 
From June 2008 – September 2010, a total 11 liver cancer patients was obtained from the 
Department of Surgery, Hospital Cattinara Trieste. The patients underwent surgical 
procedure after  indication  by hepatologist. Age of the patients ranged from 54 – 81 years old 
(70 ± 9 y) with female vs male ratio 6:5. Three patients were HCV positive. 
Three parts of the liver were taken:  neoplastic (tumoral), peripheral (between tumoral 
and ‘normal’) and distal (‘normal’) as visualized in Fig 4.1. However, distal tissues were also 
cirrhotic.  
 
 
 
 
 
 
 
 
4.2. Morphology of the Cells 
Cells population lines were obtained by culturing single cells suspension after enzymatic 
treatment. Hepatocytes usually died 1 to 2 weeks after plating. Surviving cells attach to tissue-
culture plates were routinely expanded by trypsin detachment and characterized by FACS and 
RT-PCR under sixth passage. 
Fig. 4.1. Sources of tissues for the isolation of stem 
cells. The cells were obtained from three parts of liver: 
neoplastic, peripheral, and distal tissues. 
neoplastic
peripheral
distal
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All the isolated cells from HCC and CC have fibroblastic-like morphology and attach 
strongly to the plastic tissue culture flasks. Generally, all cells have the capacity to fast 
proliferate and make colonies when they were plated in low density, indicating clonal potency 
of these cells (Fig. 4.2.A). To confirm a clonogenic anchorage-independent of cancer cells in 3 
dimensional matrixes, we diluted cells in thick gel of matrigel (BD Bioscience). As shown in 
Figure 4.3, both for dilution 1:30 and 1:60 (usually the cells were expanded in dilution 1:3), 
single clone is observed to be highly clonogenic and colonies with minimum 4 cells were 
identified. 
Growth curve of the cells were studied by plating 10,000 cells/mL in a 24-wells cell 
culture plate. Cells count was directly performed using a counting chamber under 
microscope. Growth curve of cells populations are variable among cancerous populations 
(data not shown). However, when we compared the growth of cells originated from cancers 
with one line from non-tumoral liver, the growth are significantly faster.  
The colony forming unit – fibroblast (CFU-F) is a heterogeneous cell populations derived 
from bone marrow which showed nonhematopoietic differentiation potential. These cells are 
also named as mesenchymal stem cells (MSCs). multipotent stromal cells, mesodermal stem 
cells or marrow stromal cells (all abbreviated as MSCs), mesenchymal progenitor cells 
(MPCs), multipotent adult progenitor cells (MAPCs), stromal precursors, bone marrow 
stromal stem cells (BMSSCs) or bone marrow stromal cells (BMSCs).These cells have 
characteristic to form fibroblastic colonies in small density plating. After Giemsa staining, 
these colonies could be observed macroscopically and identified as CFU-F colonies.   
The CFU-F assay was performed 3-4 weeks after plating. Macroscopically, they can be 
visualized and observed directly by the presence of purple clusters/colonies with diameter 
more than 1 mm. Microscopically, they are stained purple both in nucleus (dark purple) and 
cytoplasm (slightly light purple), and consisted at least 8 cells as shown in Fig. 4.2.B.  
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In total, 20 isolated cells were obtained consist of 7 neoplastic, 4 peripheral, and 7 distal 
regions. Only one cell populations (CSF08N) showed morphology of hepatocyte and further 
analysis was performed to identify this cells population in following results. 
 
Table 4.1. Isolated cells populations from human liver tissues 
Parameter Description n 
Period  June 2008 – September 2010   
Disease  Hepatocellular carcinoma  6 *  
 Cholangiocarcinoma  3  
 Not cancer  2 *  
Sex (F : M)  6 : 5   
Age  69.8 ± 8.9 y.o (54 – 81 y.o)   
Serology  Negative  8  
 HCV (+)  3  
Cells populations obtained  Neoplastic (N)  7  
 Peripheral (P)  4  
 Distal (D)  7  
 
* 1 line could not be maintained after 1st passage 
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Figure 4.2. Morphology of isolated cells. A. The isolated cells from HCC and CC have fibroblastic-
like morphology and capacity to attach strongly to cell culture flask. Furthermore, they are able to clone 
when plated in small density.  B. The Giemsa staining showed CFU-F colonies both macroscopically and 
microscopically.  Magnification 100x. 
 
A 
CSF01N CSF01D CSF02N CSF03N
CSF03D CSF06 CSF08N CSF08P
CSF09P CSF09D CSF10D CSF11D
B 
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Figure 4.3. Clonogenic capacity in 3 dimensional matrix of matrigel. Cells from cancerous 
tissues have a clonal capacity in anchorage-independent assay in low density concentration with 
dilution 1:30 and 1:60. Arrows indicated cell and cell colonies. Magnification 100x. 
 
4.3. Phenotype of the Cells 
 
The surface markers protein of primary cells were examined by flow cytometer with direct 
or indirect staining as described in chapter Materials and Methods. All the cells in first 
passages showed the expression of proteins CD90 and CD44 with different percentage (0.4% 
to 89.9% and 3.8% to 94.8% for CD90 and CD44, respectively) but all were negative for 
hematopoietic markers CD34 and CD45. The majority of cells lacked CD133 and CD117, 
suggesting that they are not circulating hematopoietic cells. The CD45, a marker for 
1:30
1:60
Day 0 Day 3
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lymphocytes, was checked to avoid the presence of lymphocyte with CD90 expression with 
because the cells were obtained from primary tissues. The localization of surface proteins 
CD90 and CD44 were also checked by fluorescence microscope (Figure. 4.5). 
To have a wider analysis of these primary cells, further characterizations of cell surface 
markers were carried out using real time RT-PCR on CD90 (Thy-1), CD133 (Prominin-1), 
CD45, CD44, CD34, CD29, CD31, CD105, CD117 (c-kit), and CD166 (ALCAM) as previously 
reported (Herrera et al. 2006). As control for the specificities of primer sets we used total 
RNA extract from IHH cells for CD90, Huh-7 cells for CD133 (Ma et al. 2007;Suetsugu et al. 
2006), Jurkat cells for CD34, and human liver cancer tissues and blood samples for CD34, 
CD44, CD45, CD29, CD31, CD105, and CD166. The description and function of these CDs are 
reported in Table 4.2 while the primer sequences are listed in Table 4.3. 
The qualitative PCR showed that all the cells are positive for mRNA CD90, CD44, CD29, 
CD105 and CD166, and negative for hematopoietic cell markers CD34, and CD45. They are 
also lack the expression of CD31, an endothelial molecule. An interesting observation 
indicated that high expression of CD133 and OCT4 mRNA were observed in cells with HCV 
infection compared to hepatitis-free liver cancer.  
For CSF08N cells that are morphologically almost identical to hepatocytes, RT-PCR 
results demonstrated that these cells produced high albumin and lower CD90 expression 
compared to other cells. Furthermore, they have no ability to form CFU-F colonies.  
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Figure 4.4. Frequency of cell surface marker proteins using FACS. The isolated cells were 
examined for antigens CD90, CD44, CD133, CD117, CD34, and CD45 to see the proportion of stem cells 
in the PLC.  The percentage of stem cells positivity is listed in the table. 
 
 
 
CD90
89.9%
CD45
0.0%
CD133
0.0%
CD44
95.0%
CD117
0.0%
CD34
0.0%
M1
Surface markers Frequency
CD90 (Thy-1) 0.4% - 89.9%
CD44 3.8% - 94.8%
CD133 (Prom-1) 0.0% - 1.0%
CD117 (c-kit) 0.0% - 0.5%
CD45 0.0%
CD34 0.0%
Percentage of stem cells in isolated 
cells populations
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Figure 4.5. Localization of CD90 and CD44 surface protein in primary cells. The isolated 
cells were immunostained with A) CD90-FITC and B) CD44 and antimouse-FITC. The surface marker 
proteins are localized in surface of the fibroblastic-like cells. Arrow indicates the proteins. 
 
 4.4. Expression of Albumin and AFP Genes  
Albumin and alpha-fetoprotein (AFP) are two plasma proteins synthesized by the liver 
and the yolk sac. Production of albumin and alpha-fetoprotein (AFP), marker of adult 
hepatocytes and immature liver cells, respectively, were examined by RT-PCR. For the 
specificities of both primer sets we used total RNA extract from HepG2 as control positive. 
Albumin is not/very weak expressed in majority of isolated cells, except in CSF08N and 
CSF10D (both are HCV+). The expression of AFP in isolated cells is found to be weak and 
more variable than albumin. Previously, Yamashita et al reported that AFP− cell lines had a 
subpopulation of CD90+, but AFP+ cell line did not (Yamashita et al. 2009).   
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4.5. Expression of Pluripotency Markers Genes  
Expression of OCT4 and SOX2, embryonic pluripotency transcription factors, were also 
examined by RT-PCR. For the specificities of both primer sets we used total RNA extract from 
immortalized IHH and HCC cell line HepG2 as controls positive. It had been reported that 
OCT4 is expressed in cancer and SV40 immortalized cell line (Tai et al. 2005). All isolated 
cells showed positivity of both markers, indicating a possible embryonic-like potency of these 
cells.  
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Samples 01 02 03 06 08 09 10 11
Tissues portions N N N D D N P D P D P D D
Control B-actin + + + + + + + + + + + + +
18S-RNA + + + + + + + + + + + + +
Surface markers CD90 + + + + + + + + + + + + +
CD44 + + + + + + + + + + + + +
CD29 + + + + + + + + + + + + +
CD105 + + + + + + + + + + + + +
CD166 + + + + + + + + + + + + +
CD133 - - - - - + - + - - + + +
CD117 - - - - + - + + - - + + -
CD34 - - - - - - - - - - - - -
CD45 - - - - - - - - - - - - -
CD31 - - - - - - - - - + - +
Puripotency marker OCT4 + - + + + + + + + + + + +
SOX2 + + + + + + + + + + + + +
Hepatic lineage Albumin - - - - - + - + - - - + -
CK19 + + - + + + + +
AFP - - - + - + + -
Table 4.2. Characteristic of isolated cells from PLCs using RT-PCR analysis 
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4.6. Plasticity 
4.6.1. Differentiation to adipocytes 
 
Seven primary cells (CSF01N, o2N, 03N, 03D, 08P, 08D, 09P) were subjected to 
differentiation to adipogenic lineage with specific medium. After 4 weeks, induction of gene 
PPARG, a master regulator for adipocytes differentiation, was examined using qRT-PCR and 
fat droplet in the cells cytoplasm was stained using Nile Red staining. In lipid vacuole 
staining, Nile Red dye was used instead of standard Oil Red. Both dyes are used to stain 
intracellular lipid, and Nile Red could be easily observed using both red and green 
fluorescence light under microscope.  
From all seven primary cells, only one cell CSF03D showed a clear differentiation 
potential to adipocytes as demonstrated with drastic up-regulation of PPARG gene and 
deposition of lipid vacuoles in the cytoplasm (Figure 4.6). CSF03D cell is originally obtained 
from distal part or a CC patient with a histological moderate degree of cancer differentiation. 
We assume that this cell might be most closely related to ‘normal’ compared to the others 
which allows differentiation. Even though adipogenic-differentiation capacity is observed in 
only one cell population, this data demonstrated the capacity of the SCs or CSCs obtained 
from liver cancer and cirrhotic. This data is concordant with previous one that SCs with 
CD90+ phenotype from fetal liver have capacity to transform into adipocytes (Dan et al. 
2006). Furthermore, this data gives a wider comprehension from previous reports of normal 
hLSCs and CSCs (Herrera et al. 2006;Yang et al. 2008) that CD90+ cells from adult diseased 
tissue may still have capacity for trans-differentiation.  
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Figure 4.6. Cells-directed differentiation to adipogenic lineage. A. Quantitative RT-PCR 
result of gene PPARG showed an up-regulation of PPARG in one cells population 03D. The expression 
of basal 03D as control= 1.00. The target mRNA expression was normalized to reference gene β-actin. 
B. Nile Red staining of lipid vacuoles in the cytoplasm under fluorescence microscope of cells  CSF03D.  
Arrows indicates lipid vacuoles.  
0
4
8
12
16
01N 02N 03N 03D 08N 08P
F
o
ld
s 
o
f 
m
R
N
A
 e
xp
re
ss
io
n
cells populations
PPARG 
control
induction
Fluorescence 
microscope
A. Control B. Induction
Confocal 
microscope
Hoechst + Nile Red Hoechst + Nile Red
Nile Red Nile Red
B 
A 
Chapter 4 – Result 1 
Identification of Stem Cells from Human Primary Liver Cancers 
 
73 
 
4.6.2. Differentiation to pancreatic cells 
 
To check whether the isolated cells have capacity to differentiate into endodermal lineage, 
we induced the cells towards pancreatic cells. Data of pancreatic differentiation presented in 
this report is an ongoing study and a further examination is still under analysis. 
Seven primary cells (CSF01N, o2N, 03N, 03D, 08P, 08D, 09P) were subjected to 
differentiation into pancreatic cells by exposure to 10 mM nicotinamide (Herrera et al. 
2006;Yang et al. 2002). The sorted JHH-6 with similar phenotype JHH6 CD90+CD44+ and 
its counterpart JHH6 CD90-CD44+ were used as phenotype control. Further description of 
these sorted cells may be found in subchapter 4.9. After 12-18 days, qRT-PCR on genes 
related with endocrine differentiation somatostatin (SST) and gastric inhibitory poplypeptide 
(GIP) were examined. A control universal mRNA from pancreatic tissues was used as SST 
primer control (data not shown). 
As shown in Figure 4.7, five from seven cells population showed expression and up-
regulation of SST and GIP with variable folds of up-regulation. In CC samples, the SST gene is 
expressed even in basal condition. 
 
 
 
 
 
 
 
 
Chapter 4 – Result 1 
Identification of Stem Cells from Human Primary Liver Cancers 
 
74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Cells-directed differentiation to pancreatic cells. After nicotinamide induction, 5 
primary cells showed induction and up-regulation of SST and/or GIP mRNA. The sorted JHH6 CD90+ 
and CD90- cells were used as control. A. The qualitative result based on gel electrophoresis, actin 
mRNA was employed as internal reaction control. B. The quantitative result based on qRT-PCR, 
expression of basal 01N and 02N were control = 1.00 on gene SST and GIP, respectively. The target 
mRNA expression was normalized to reference gene β-actin.  
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4.7. Xenograft Assay: Pilot Study 
 
To check whether primary cells with CD90+CD44+ phenotypes have the capacity to act as 
real CSCs in liver cancer we injected subcutaneously these cells with a minimal 80% positivity 
into athymic male nude FOXN1(nu/nu) homozygotes mice. Cells CSF01N (poorly 
differentiated CC) and CSF09P (HCC with cirrhosis) were selected for this pilot study for 
their fast growth capacity as compared to the other cells. One million of sorted cells from 
established cell line JHH6 CD90+ and JHH6 CD90- were used as positive and negative 
control. The viability of cells was checked using tryphan blue exclusion assay after injection 
and showed more than 95% viability. The xenograft assay is described in Table 4.3. 
Four months after injection, no sign of tumor nodules were observed in all injected mice. 
Positive control mouse (1 million cells CD90+) died 10 days after injection, but negative 
control mouse (1 million CD90-) survived. Those mice were injected with same origin cells 
JHH-6 but with different CD9 phenotype. All mice did not show any particular behavior. 
Interestingly, body weights of all mice injected with CD90+CD44+ were 10% higher than 
mouse injected with CD90- cells and control mice without treatment (data not shown). 
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Table 4.3. Pilot study of xenograft assay: preliminary result 
Control Cells ID Sources Serology Concentration Tumor after 4 mos 
Control 
mouse 
- - - - 0/2 
Control (+) JHH6 
CD90+ 
Cell line 
HCC 
HCV(-) 
HBV(-) 
1,000,000 † day 10 
Control (-) JHH6 
CD90- 
Cell line 
HCC 
HCV(-) 
HBV(-) 
1,000,000 0/1 
Primary 
cancers 
CSF01N CC HCV(-) 
HBV(-) 
10,000 0/1 
50,000 0/1 
500,000 0/1 
CSF09N/P HCC HCV(-) 
HBV(-) 
10,000 0/1 
50,000 0/1 
500,000 0/1 
 
4.8. Expression of ABCG2 Gene 
 
To explore the expression of drug-resistant-protein ABCG2 in isolated cells populations, 
qRT-PCR was performed. As predicted, ABCG2 expression is found to be variable, just as the 
result of tissues samples (please refer to Chapter VI). As shown in Figure 4.8, the distribution 
of ABCG2 may be higher in peripheral or distal tissues. However, variations of ABCG2 
expression may vary among individuals due to different tissues types and intrinsic factors, 
such as age and type of HCC treatment exposure.  
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Figure 4.8. ABCG2 mRNA expression in isolated cells populations. The ABCG2 expression is 
found to high variable among samples.  ABCG2 expression was normalized to reference gene β-actin 
and expressed as au compared to sample 03D.  
 
The result of ABCG2 mRNA expression in isolated each cells populations is separated 
from result from whole tissues samples because ABCG2 is also expressed in mature cells such 
as hepatocytes, cholangiocytes, and liver blood vessel endothelium (Maliepaard et al. 2001) 
(Fetsch et al. 2006;Komuta et al. 2008). Regarding this reason, a direct comparison between 
isolated cells which are ‘more’ homogenous with liver tissues which are more ‘heterogeneous’ 
may give a bias result. Result of ABCG2 mRNA expression in tissues samples is reported in 
Chapter VI. 
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4.9. Progression to Cancer Heterogeneity: JHH-6 Model  
 
JHH-6 (JCRB1030) is a hepatoma cell line originated from a female Japanese HCC 
patient with hepatitis B surface antigen serogenative HBs-Ag(-), HBs-Ag(-). These cells have 
undifferentiated morphology. Albumin, AFP and CEA were not observed in the supernatant 
of the cell culture but ferritin was found to be secreted (6.7 ng/ml).  
In basal level, JHH-6 cells express CD90 and CD44 mRNA. When they were checked by 
FACS, they have a frequency of 0.1% CD90 and almost 100% of CD44 (data not shown). To 
see the difference between CD90+ and CD90- cells, they were sorted based on its CD90 
phenotypes using a MACS magnetic sorter with 99% purity as mentioned in Materials and 
Methods section. The sorted cells has phenotypes JHH-6 CD90+CD44+ and its counterpart 
CD90-CD44+. By RT-PCR, both cells express CD29, CD105, and CD166, negative for CD34 
and CD45, and weak expressed CD31. This phenotype is similar with the isolated cells in 
primary culture. 
The purity of the CD90 cells at P°1 after sorting was confirmed by RT-PCR of total RNA, 
immunofluorescence of fixed cells, and Western blot of membrane fraction protein. As shown 
in Figure 4.9, sorted cells showed distinct characteristics. RT-PCR analysis demonstrated that 
positive fraction cells expressed around 45-folds more CD90 mRNA, while negative cells have 
similar expression of control. Immunofluorescence data showed that only positive fraction 
had a clear CD90 protein in cells membrane. Similar result was also obtained by Western blot 
where a band of CD90 25-35 kDa is observed in membrane extract of positive but not 
negative fraction. Immortalized cell line IHH is used as control.  
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Figure 4.9. Purity of sorted JHH-6 CD90+ and CD90-. A. Quantitative RT-PCR result. The 
expression of unsorted JHH-6 as control = 1.00.  The mRNA expression was normalized to reference 
gene 18S-rRNA and β-actin. B. Immunofluorescence  andWestern blot of CD90 protein from membrane 
extract fraction resulting a 25 – 35 kDa protein band [Experiments were performed together with B. 
Anfuso]. 
 
 
After sorting and confirmation of the purity, the cells phenotype from both positive and 
negative fractions was followed-up until the 15th  passage. An interesting change is observed 
as CD90+ cells could differentiate into CD90+ and CD90-. In contrast, the CD90- cells can 
harbour only CD90- cells, as shown in Figure 4.10.  Until the 21st passage after sorting, CD90+ 
cells reached a composition of positive and negative fraction of about 20% and 80%, 
respectively. Until passage 21st, CD90- cells can be only 100% CD90- cells. There are no 
morphological differences in our JHH6 CD90+ and CD90- cells, checked by FACS and 
microscopy. 
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Figure 4.10. Progression of JHH-6 CD90+ cells to comprise cancer heterogeneity. Cells 
JHH-6 CD90+ could differentiate into both phenotypes CD90+ and CD90-, its positivity diminished 
along cells passages; in contrast CD90- could harbor only CD90- [Experiments were performed 
together with B. Anfuso]. 
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5.1. Human Liver Tissues 
 
As mentioned in the General Introduction, beside the use of the stem cells markers in the 
isolation of putative CSCs from human disease, they might have clinical significances in 
human disease. From this viewpoint, the expression of stem cells markers might be also 
useful in the clinical settings. To search a possible relationship between these markers with 
the disease progression in human liver diseases, a gene expression study on several most 
common hepatic stem cells markers was performed. The genes examined consist of CD90, 
EpCAM, CD133, OCT4, CK19, and CK7.  
We examined several liver malignancies: HCC (n=28), CC (n=3), pediatric 
hepatoblastoma HB (n=7), other benign tumors O (n=5), biliary atresia BA (n=5), and young 
and adult normal tissues N (n=12). Other tumors included were hamartoma and 
pseudotumor. The number of patients and total tissues size is described in Table 5.1. Biliary 
atresia (BA) is a non neoplastic neonatal liver disease in which the bile ducts is absent. As the 
biliary tract is disrupted, the liver cannot deliver bile into the intestine and its accumulation 
resulted in liver fibrosis and eventually liver cirrhosis. Due to small number of CC samples, 
they are not included in the distribution graphs and used as positive control for expression of 
EpCAM, CK19 and CK7.  
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Table 5.1. Description of tissues types for SCs markers mRNA distribution analysis 
Disease groups Patients no. Samples no. Tissues types 
HCC 12 28 Neoplastic, peripheral, and 
distal tissues 
CC 2 3 Neoplastic and distal tissues 
HB 4 7 Neoplastic and distal tissues 
O 4 5 Diseased and ‘normal’ tissues 
BA 5 5 All cirrhotic tissue 
N 12 12 Normal tissues 
 
5.2. Distribution of CD90 (Thy-1) 
 
The CD90 mRNA levels from the 52 tissues samples analyzed, estimated by qRT-PCR, are 
expressed as arbitrary units (au), compared to a normal sample (1.00 au). The CD90 gene is 
expressed in all tissues examined. In normal donor livers, CD90 mRNA expression is more 
limited and homogenous, ranges from 0.05 to 1.00 au and in BA from 0.24 to 1.91 au. In both 
HB and HCC, CD90 mRNA expression is found to be more variable than in normal tissues. 
The lowest is identified in the distal tissues of both tumors with an expression value of 0.29 
and 0.11 au, respectively, and to be highest in neoplastic tissues of 6.05 and 5.99 au, 
respectively. As shown in the Figure 5.1, the overall distribution of CD90 mRNA in hepatic 
malignancies has a clear distinguished pattern. The CD90 expression in cirrhotic and liver 
cancers is significantly difference with normal liver tissues (p<0.05 for HB and BA, p<0.01 
for HCC). 
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Figure 5.1. Distribution of CD90 mRNA in human liver. CD90 expression is normalized to three 
reference genes 18S-RNA, β-actin, and GAPDH, and is expressed as au compared to one normal tissue. 
Samples size: Normal N = 11; Hepatoblastoma HB = 7; Hepatocellular Carcinoma HCC = 17; Biliary 
atresia BA= 5. Student’s t- test * p<0.05, ** p<0.01. 
 
5.3. Distribution of EpCAM 
 
The EpCAM mRNA levels in the of 43 tissues samples analyzed and estimated by qRT-
PCR, are expressed as au compared to a normal sample (1.00 au). The EpCAM gene is 
expressed in all tissues but one HCC neoplastic sample in which EpCAM expression was very 
low. As a positive control, EpCAM expression in CC tissues was more than 1000 folds 
compared to control was used. In normal donor livers, its expression ranges from 0.11 to 
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10.37 au and in BA 3.55 to 18.94 au In liver cancers, it is found to be very high variable, 
ranging from 0.85 to 201 au and 0.093 to 557 au in HB and HCC, respectively. This variability 
had been also reported in HCC where protein expression was assessed by IHC  (Yamashita et 
al. 2009). As shown in Figure 5.2, the distribution of EpCAm mRNA in hepatic malignancies 
has a distinguished pattern similar to the CD90 distribution. EpCAM expression in normal 
tissues is more homogenous than liver diseases and EpCAM expression in cirrhotic and liver 
cancers BA, HB, and HCC are significantly difference with normal liver tissues (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Distribution of EpCAM mRNA in human liver. EpCAM expression is normalized to 
three reference genes 18S-RNA, β-actin, and GAPDH, and is expressed as au compared to one normal 
tissue. Samples size: Normal N = 6; Hepatoblastoma HB = 7; Hepatocellular Carcinoma HCC = 18; 
Biliary atresia BA= 5. Student’s t- test * p<0.05. 
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5.4. Distribution of CD133 (Prominin-1) 
 
The CD133 mRNA levels of a total of 59 tissues samples were analyzed, by qRT-PCR. 
Interestingly, not all the samples express CD133 mRNA, even in neoplastic tissues. This result 
is concordant with previous report that showed CD133 positivity only in about 70% of  HCC 
tissues (Lingala et al. 2010). Figure 5.3 shows the distributions of the CD133 in positive 41 
samples. In normal donor livers, CD133 expression ranges from 0.07 to 1.00 au and in BA 
ranges from 0.40 to 2.60 au In liver cancers, its expression was  highly variable ranging from 
0.03 to 2.93 and 0.05 to 1.21 au in HB and HCC, respectively.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Distribution of CD133 mRNA in human liver. CD133 expression is normalized to 
three reference genes 18S-RNA, β-actin, and GAPDH, and is expressed as au compared to one normal 
tissue. Samples size: Normal N = 12; Hepatoblastoma HB = 7; Hepatocellular Carcinoma HCC = 9; 
Biliary atresia BA= 5. Student’s t- test ** p<0.01. 
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As shown in Figure 5.3, the distribution of CD133 mRNA in hepatic malignancies is found 
to be more unevenly distributed as compared to CD90 and EpCAM. There is no significant 
difference between CD133 expression between normal tissue and liver cancers. However, 
CD133 mRNA is preferably expresses in cirrhotic liver BA (p<0.05 to N).  
 
5.5. Distribution of OCT4 
 
OCT4, an embryonic pluripotency transcription factor, is closely-associated with 
embryonic stage and pre-fetal. The OCT4 mRNA levels from a total of 45 tissues samples 
analyzed in this study, estimated by qRT-PCR, are expressed as au, compared to a normal 
sample as 1.00 au In normal donor livers, its expression ranges variably from 0.01 to 1.00 au 
and in BA from 0.53 to 2.60 au In liver cancers, its expression is found also to be scattered 
and  ranges from 0.26 to 3.49 and 0.28 to 1.31 au in HB and HCC, respectively. There is no 
significant difference between OCT4 expression between normal and liver cancers (Figure 
5.4).  
However, it is really important to pay intention that the identification of OCT4 mRNA is 
debatable, especially in adult tissues. Even though this data may represent distribution of 
OCT4 in transcription level, further analysis in protein level such as immunostaining must be 
conducted. 
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Figure 5.4. Distribution of OCT4 mRNA in human liver. OCT4 expression is normalized to 
three reference genes 18S-RNA, β-actin, and GAPDH, and is expressed as au compared to one normal 
tissue. Samples size: Normal N = 9; Hepatoblastoma HB = 7; Hepatocellular Carcinoma HCC = 13; 
Biliary atresia BA= 5.  
 
5.6. Distribution of Cytokeratin 19 and Cytokeratin 7 
 
Beside studies of surface markers expression, we decided also to examine cytokeratins 
(CK) CK19 and CK7 mRNA distribution in liver. CK19, and perhaps CK7, are epitopes 
recognized by OV6 antibody together with CK14. Expression of CK19 and CK7 are found to be 
high in bile duct cancer as a result of high proliferation of cholangiocytes . Based on this 
knowledge, we used three tissues of CC as positive controls of the reaction. The CK19 and CK7 
mRNA levels were assessed in in 48 tissues samples by qRT-PCR, expressed as au  compared 
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to a normal sample with value 1.00 au For CC samples, the mRNA levels of CK19 and CK7 
were 118.97 and 10.47 au, respectively. 
 
 
 
 
 
 
 
 
Figure 5.5. Distribution of cytokeratin 19 and cytokeratin 7 mRNA in human liver. mRNA 
expressions are normalized to three reference genes 18S-RNA, β-actin, and GAPDH, and are expressed 
as au compared to one normal tissue. Samples size: Normal N = 10; Hepatoblastoma HB = 7; 
Hepatocellular Carcinoma HCC = 17; Biliary atresia BA= 5. Student’s t- test ** p<0.01. 
 
As shown in Figure 5.5, in normal livers CK19 expression ranges from 0.02 to 1.00 au and 
from 1.77 to 3.39 au in BA. In HCC, it ranges from 0.10 in distal and 1.94 in neoplastic tissue 
and from 0.03 to 2.52 au in HB. There is a significant difference of CK19 expression between 
BA and normal tissues (p<0.01). For CK7, its expression ranges in normal liver from 0.03 to 
1.36 au and in  0.81 to 4.12 au BA. In HB and HCC, it ranges from 0.05 to 5.85 and 0.06 to 
2.93, respectively. There is no significant difference among all groups.   
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To summarize, the list of values of gene expression result of stem cells markers examined 
in hepatic malignancies is described in Table 5.2, as compared to a normal liver sample, In 
the case of  HB and HCC, data report  both neoplastic tissues and cirrhotic tissues. 
 
Table 5.2. Gene expression data expressed as arbitrary unit in several hepatic malignancies. 
Data report the median value and the interval for each category 
 mRNA expression values in arbitrary unit (median [min-max]) 
 Normal BA HB HCC 
CD90 0.31 (0.05-1.00) 1.22 (0.24-1.91) 0.71 (0.29-6.05) 1.34 (0.11-13.33) 
EpCAM 0.73 (0.11-1.00) 6.20 (3.55-18.94) 3.82 (0.85-201.40) 2.92 (0.41-557.57) 
CD133 0.18 (0.07–1.00) 2.27 (0.40–2.60) 0.30 (0.03-2.93) 0.32 (0.05-1.21) 
OCT4 0.33 (0.01 – 1.00) 0.62 (0.53–2.60) 0.49 (0.26-3.49) 0.50 (0.25-1.31) 
CK19 0.37 (0.02-1.00) 2.63 (1.77-3.39) 0.48 (0.03-2.52) 0.63(0.10-1.94) 
CK7 0.53 (0.03-1.36) 2.50 (0.81-4.12) 0.80 (0.05 – 5.85) 1.22 (0.06-2.93) 
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5.7. Differential Expressions between Neoplastic and Distal 
Tissues 
 
To observe the differential expression due to the genes up-regulations in the tumoral 
compared to non tumoral tissue (distal) of liver cancers, we studied the mRNA expressions of 
several SCs markers described above in paired samples of the same patient. As we assumed 
that the basal expression of these genes varies in every patient, the comparison in each 
individual will give a more meaningful and relevant information on the possible regulation. In 
total, we checked 8 paired tissues from cancer patients, consisting in 3 HB (HB-1, HB-2, and 
HB-3), 4 HCC (HCC-1, HCC-2, HCC-3, and HCC4), and 1 CC (CC-1). The differential 
expressions between neoplastic to distal were calculated using the ratio: neoplastic mRNA / 
distal mRNA. Ratio more than 1.00 indicated folds of higher expression in neoplastic tissues 
in individual sample. 
As shown in Figure 5.6, the most interesting pattern is observed for CD90 and EpCAM. 
Almost all samples showed drastic up-regulations in neoplastic compared to distal tissues. 
Expressed as median (min – max), folds of up-regulations are 9.27 (0.56 – 18.24) and 41.51 
(0.04 – 235.83) for CD90 and EpCAM, respectively. The data of CD90 mRNA was also 
verified by protein expression by Western Blot (Figure 5.7). For OCT4, all samples showed a 
homogenous though modest up-regulation with a median value 1.13 (0.19 – 3.66). For CK19, 
the difference is more variable with values ranging from 0.07 – 27.56 (median 1.82). 
Interestingly, in HCC samples, differential expressions of CK19 and CK7 seem to be 
complementary: high up-regulation of CK19 is accompanied with lower up-regulation of CK7, 
and vice versa.  
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Figure 5.6. The mRNA differential expression between tumoral and distal tissues in 
human liver cancer. Stem markers genes analyzed CD90, EpCAM, CD133, OCT4, CK19 and CK7.  
Value of ratio >  1.00 indicated higher expression in tumoral (neoplastic) than distal. HB = 
hepatoblastoma, HCC = hepatocellular carcinoma. 
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Figure 5.7. The CD90 protein differential expression between tumoral and distal tissues 
in human liver cancer. Normal = normal liver, HCC = hepatocellular carc inoma, HB = 
hepatoblastoma.   
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5.8. Distribution of Ct values 
 
Another helpful way to check the variability of target genes expression in the sample is by 
checking the distribution of cycle threshold (Ct) values in the PCR reaction. Even though gene 
expression analysis must be calculated with normalization to reference genes and the 
efficiency of the primers, graphic of Ct would give a direct comparison between two samples 
groups within same gene. For qRT-PCR we used similar quantity 25 ng of cDNA for all genes.  
We compared the ct values of all target genes CD90, EpCAM, CD133, OCT4, CK19, and 
CK7 in groups of normal liver and neoplastic nodules. Neoplastic nodules examined in this 
study included HCC, CC, and HB. The scheme in Figure 5.8 shows the minimum and 
maximum Ct of the samples: 
i. The Ct values of three housekeeping genes used are relative stabile in normal and 
diseased tissues.  
ii.  The distribution of Ct values of normal tissues is more limited than neoplastic 
nodules for all genes, particularly for the CD90 gene. 
iii. Lower Ct values in neoplastic nodules means higher template in the samples, i.e. 
higher expression of the target gene. 
 
The mean values of Ct of these groups are described in Table 5.3, (mean ± SD). In 
concordance with data of gene expression of CD90 and EpCAM, the difference of the Ct 
between normal liver and neoplastic nodules is clear for both genes. It is important to put 
attention that the PCR condition, experimental set up, and efficiency of primer sets of 
different target genes are variable, and the direct comparison of Ct distribution is only valid 
for sample in the same genes and not among different genes. 
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Figure 5.8. The distribution of cycle threshold (Ct) values of qRT-PCR in liver cancers. A 
scheme of distribution of Ct values of reference genes and target genes of  A. normal liver donor, and B. 
neoplastic nodules of PLCs HB, HCC, and CC. Bar graphic represents minimum and maximum Ct. 
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Table 5.3. Cycle threshold values of qRT-PCR of normal tissues and neoplastic nodules of 
human PLCs. Values are expressed as mean ± SD 
 
 Ct values (mean ± STD) 
Target genes Normal tissues Neoplastic nodules 
CD90 30.54 ± 0.94 27.48 ± 1.65  
EpCAM 30.31 ± 3.37 27.00 ± 4.56 
CD133 33.51 ± 1.90 32.22 ± 2.79 
OCT4 27.34 ± 2.37 26.62 ± 1.55 
CK19 28.75 ± 1.46 27.72 ± 2.87 
CK7 27.16 ± 1.88 26.40 ± 2.37 
 
 
 
 
 
 
 
 
 
  
 
Chapter VI – Result 3 
ABCG2 Expression: Drug Resistance and 
CSCs 
 
 
 
 
 
 
 
 
Chapter 6 – Result 3 
ABCG2 Expression: Drug Resistance and CSCs 
 
96 
 
6.1. Distribution of ABCG2 mRNA in Human Liver Tissues 
 
Even though ABCG2 is associated with CSCs marker, the ABCG2 study was separated 
from previous analysis because the use of ABCG2 is more based on its functional activity. 
ABCG2 is also expressed in mature cells. In this chapter, we report the study on the 
expression of ABCG2 both in vivo in clinical tissues samples and in vitro in hepatic cell line 
models. 
The ABCG2 mRNA levels from 59 tissues samples was analyzed and estimated by 
quantitative real time PCR. Values  are expressed in arbitrary units (au), compared to a 
normal sample to which a value of  1.00 au is given.  
As shown in Figure 6.1, the ABCG2 mRNA expression in normal liver is related with age. 
ABCG2 expression in children (age 3 to 14 y) is lower compared to adults (age 25 to 68 y) with 
mean value of 2.84 ± 2.38 and 13.77 ± 8.95, respectively, with  expressions ranging from 0.92 
– 7.26  in children and 4.08 – 23.07 in adults (p<0.05). This consequence is likely due to the 
function of ABCG2 itself to protect the cells from extra compounds and person with older age 
are tend to receive more exposure to drugs and other compounds than children. 
The ABCG2 mRNA expression is observed to be highly variable (au. ranged from 0.41 in a 
BA patient to 56.63 in a HCC). The ABCG2 expression in BA is the most homogenous 
compared to other groups. Low levels in ABCG2 expression are found mainly distributed in 
BA patients and young normal livers, whereas the highest ones are observed in tissues 
originating from HCC, HB, and other malignancies (Figure 6.2). The expression of group 
HCC to group normal liver is significantly different (p<0.05).  
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Figure 6.1. ABCG2 mRNA expression in normal liver tissues. The ABCG2 expression is 
concordant with age (n = 11, children: 3 – 14 y, adult: 25 – 68 y). ABCG2 expression is normalized to 
three reference genes 18S-RNA, β-actin, and GAPDH, and expressed as au compared to one child tissue 
= 1.00 au.  
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Figure 6.2. ABCG2 mRNA expressions in several hepatic malignancies. ABCG2 expression 
was normalized to three reference genes 18S-RNA, β-actin, and GAPDH, and expressed as au compared 
to one normal tissue. Sample size: Normal N = 10, Biliary atresia BA = 5, Hepatoblastoma HB = 7, 
Hepatocelular carcinoma HCC = 28 and Other tumors O = 5. Student’s t- test * p<0.05, *** p<0.001 
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6.2. Expression of ABCG2 against drug therapy: models in vitro  
 
Previous data demonstrated the expression of ABCG2 in human tissues. However, the 
limitation of the result is that  as treatments may influence the expression of the transporter 
and samples without this intrinsic and unavoidable bias are not available, the real “normal” 
value cannot be assessed. To overcome this issue, several hepatic cell lines were used to see 
the effect of the treatment. For this reason the use of cell lines derived from human liver 
cancer may help in unravel this limitation.  
Four human hepatic cell lines with different stage of differentiations were analyzed 
(Figure 3.1). We used immortalized hepatocytes IHH, well-differentiated HCC HepG2 and 
HuH-7, and poor-differentiated HCC JHH-6. We checked albumin transcription markers for 
hepatic markers on these cell lines. Albumin mRNA was detected in HepG2 and HuH-7, but 
not in JHH-6 cells. We assume that differentiated cancer cells HepG2 and HuH-7 may still 
function to produce albumin, but not undifferentiated cells JHH-6 (data not shown).  
As shown in Figure 6.3, a close relation is observed between cells differentiation and 
ABCG2 expression. With the expression in IHH cells defined as 1.00 au, the highest level of 
ABCG2 mRNA expression was observed in the most undifferentiated cells JHH-6 (76.27 ± 
6.00), followed by the more differentiated cells HepG2 (53.52 ± 19.06) and  HuH-7 (35.07 ± 
10.96). In line with the mRNA results, the ABCG2 protein (72 kDa) is detected in membrane 
fraction of tumoral cell lines HuH-7, HepG2, and JHH-6, but not in IHH (Figure 6.4). 
 
 
 
Chapter 6 – Result 3 
ABCG2 Expression: Drug Resistance and CSCs 
 
100 
 
Cells differentiation
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Basal ABCG2 mRNA and protein expression in hepatic cell lines. The basal 
ABCG2 mRNA was found to be highest in less differentiated cells JHH-6 than differentiated cells HuH-7 
and JHH-6 and immortalized hepatocytes IHH. IHH expression was used as control (1.00 au). 
Student’s t- test: ** p<0.01 to cells IHH; # p<0.05 and ##  p<0.01 to cells HuH-7. 
 
To functionally asses the ABCG2 activity in response to drug exposure, we assessed the 
cytotoxicity effect to these cells by a 24 hour exposure to 5 µM doxorubicin, a drug used in the 
treatment of liver cancer. As shown in Figure 6.4, after 24 hours of incubation, this dose is 
cytotoxic to about 50% cells populations as assessed by MTT assay. To explore the effect of 
similar dose and similar treatment time of doxorubicin to different cell lines, we decided to 
expose these cell lines to mentioned dose and duration. 
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Figure 
6.4. 
Cells 
viability after dose-dependent DOX treatment for 24 hours. The cells were treated with 0.0 – 
10.0 µM of doxorubicin for 24 hours. All cells showed more less 50% viable in 5 µM dose. Viability of 
cells were assayed using MTT dye reduction test with un-treated cells used as control. 
 
 
As shown in Figure 6.5, the exposure to doxorubicin induces an up-regulation of ABCG2 
mRNA in all the cell lines tested. Interestingly, the extent of the up-regulation is inverse to 
the basal level of expression as IHH and HuH-7 show a significant increment of gene 
expression (15.25 ± 4.45 and 9.36 ± 0.48 folds, respectively) compared to HepG2 and JHH-6 
(1.14 ± 0.68 and 1.38 ± 1.58 folds, respectively). As in the human tissues, qualitative protein 
blots from total membrane fraction followed the level of the gene expression. In basal 
condition of IHH cells, the ABCG2 protein band (72 kDa) is not detected, but it is noticeable 
after exposure to doxorubicin. The same occurred in HuH-7 while no difference is observed in 
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expression of the transporter (Figure 6.5).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. ABCG2 mRNA and protein expression after exposure to 5 µM doxorubicin for 
24 hours. mRNA up-regulations of ABCG2 were observed in all cell lines with different folds. Student’s 
t- test ** p<0.01 compared to basal expression (inset: protein blots). 
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6.3. Activity of ABCG2 
 
To assess the activity of the ABCG2 protein, we used the Hoechst 33342 efflux functional 
assay where lower intracellular fluorescence indicates smaller dye content due to a higher 
efflux from the cell. To establish the potential role of ABCG2 in this system, the assay was 
performed in the absence and presence of verapamil, a potent ABCB1 inhibitor but a weak 
ABCG2 inhibitor (Zhang et al. 2005).  
Preliminary experiments demonstrated no effect on cell viability (MTT test) by either 
Hoechst 33342 or verapamil up to at concentration of 20 µM and 10 µg/mL, respectively. 
Moreover, 3 hours time frame also does not affect cells viability (data not shown). The intake 
fluorescence dye value is defined as au with normalization with the amount of total protein 
using a complex Copper-BCA assay. The IHH cell line is excluded in functional test because of 
a very low ABCG2 basal expression.  
The efflux potential is concordant with the increase concentration of Hoechst (2.5 – 10.0 
µg/mL) in all three cell lines tested. Considering the intracellular dye intake of 2.5 µg/mL 
Hoechst as 100% (1.00 au), the dye content decreases for as much as 47%, 49%, and 46% in 
HuH-7, HepG2, and JHH-6 cell lines (Table 6.1).  
In the presence of 1 µM verapamil, the difference of the intracellular dye intake with and 
without verapamil indicates the ABCG2 efflux activity. Higher amount intracellular intake 
fluorescence indicates lower efflux capacity. Among all three cell lines, the smallest difference 
with and without verapamil is observed in JHH-6 indicating that ABCG2 efflux capacity was 
dominant in JHH-6 compared to HepG2 and HuH-7 (Figure 6.6).  
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Table 6.1. The Hoechst efflux capacity of the HCC cell lines 
Hepatoma cell 
lines 
The intracellular dye intake of Hoechst 33342 (% au) 
2.5 µg/mL 5.0 µg/mL 10.0 µg/mL 
HuH-7 100.0 ± 6.4 88.4 ± 5.5 53.0 ± 2.8 
HepG2 100.0 ± 6.2 74.7 ± 3.1 51.2 ± 2.8 
JHH-6 100.0 ± 5.8 80.1 ± 2.1 53.7 ± 4.0 
 
 
 
 
 
 
 
 
 
Figure 6.6. Functional capacity of ABCG2 to export the Hoechst 33342. Difference in 
intracellular content with and without the ABCB1 inhibitor verapamil was observed to be small in JHH-
6 followed by HepG2 and HuH-7 indicating major functional activity of ABCG2 in JHH-6. The 
intracellular intake of HuH-7 with Hoechst 33342 was considered as 100 % au. All the results were 
normalized to total protein quantification. 
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7.1. The stem cells population in primary liver cancers 
 
The evidences of CSCs hierarchy theory had been demonstrated by several studies, both 
in circulating or solid tumors. A small population of cells of the cancer with distinct 
phenotype has the ability to induce tumor in xenograft model and might have potency to 
differentiate into multiple lineages. Until now, evidences of the identifications in liver cancer 
are still very limited.  
In this thesis, in period 2008 – 2010, we isolated a population of cells from 3 parts of 
liver cancer HCC and CC: neoplastic nodules, peripheral tissues, and distal tissues. As shown 
previously in Chapter 4, the cells have phenotypes CD90+ and CD44+, but however, they are 
also positive for MSCs markers mRNA CD90, CD44, CD105, CD166, and CD29, and negative 
for endothelial marker CD31, and hematopoietic cells CD34 and CD45. These phenotypes 
were found in all cells populations from all 3 parts liver cancers. Several populations positive 
for AFP and albumin indicate a partial commitment to hepatic lineage. In addition, samples 
with HCV positive seem also to express CD133 and higher OCT4.  
 As shown in Figure 4.2 and 4.3, these cells have spindle-shape like fibroblasts 
morphology and they have capacity to form clonal colonies, both on plastic surface and three 
dimensional matrix indicating anchorage-independent and clonogenic capacity. This 
phenotype had been reported as indicative of human liver stem cells (HLSCs) isolated from 
adult normal liver. The HLSCs were able to differentiate in mature hepatocytes, even 
osteogenic and endothelial cells. Furthermore, they contributed to regeneration of liver 
parenchyma in severe-combined immunodeficient mice. However, the HLSCs could not be 
differentiated into adipogenic lineage (Herrera et al. 2006).   
MSCs or commonly known also as stromal stem cells are non-hematopoietic precursor 
cells, mainly found in bone marrow, which contribute to the maintenance and regeneration of 
wide varieties of mesoderm lineage such as bone, cartilage, muscle, and adipose tissues (Stagg 
2008). Moreover, cells co-purified with MSCs and named as multipotent adult progenitor 
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cells (MAPCs) differentiated at single cell level not only into mesenchymal cells but also in 
cells with visceral mesoderm, neuroectoderm, and endoderm in vitro (Jiang et al. 2002). The 
MSCs are capable to adher to plastic cell culture flask and are identified as on specific surface 
markers that distinguish these cells from others.. The MSCs in human and mouse must 
positive for CD105 (endoglin), CD73 (ecto-5’-nucleotidase) and CD44 (hyaluronate receptor) 
and for negative for CD31 (endothelial cell marker) and CD45 (hematopoietic cell marker). 
The MSCs are found not only in bone marrow, but also in many adult tissues. Because of 
their differentiation capacity, the MSCs become good tools in regenerative medicine. The 
MSCs isolated from bone marrow and cord-blood can be differentiated into hepatocytes-like 
in vitro, including production of albumin, glycogen storage, urea secretion, uptake of low 
density lipoprotein, and phenobarbital-induced cytochrome P450 activity (Lee et al. 2004). 
Furthermore, hepatocytes derived from adipose-MSCs could expand and integrate into liver 
parenchyma in mice model (Banas et al. 2007). Beside MSCs in normal tissues, the MSCs in 
human solid cancers have also been reported in various types of cancers such as breast 
cancer, glioma, and many others (Karnoub et al. 2007;Nakamura et al. 2004).  
Based on the mRNA data, our cell populations are fit with suggested MSCs population 
identification from the Mesenchymal and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy (Dominici et al. 2006; Horwitz et al. 2005). The committee 
proposed three minimal criteria to name cells as MSCs: 1) plastic adherent behavior in 
standard culture condition; 2) expression of CD105 and CD90, but not CD45, CD34; 3) 
possible potency to differentiate into mesenchymal lineage in vitro. 
We performed also trans-differentiation experiments. As reported, cells with this 
phenotype obtained from normal liver could be differentiated not only into mesodermal 
lineages, but also into endodermal lineage (Herrera et al. 2006). However, because our cells 
populations were obtained from cancerous tissues, their multipotent capacity might be more 
restricted compared cells from bone marrow and normal tissues. Furthermore, these cells 
have limited growth when they were plated in specific medium for MSCs, indicating different 
behavior of these cells compared to normal MSCs obtained from normal bone marrow or 
tissues. 
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We tried to induce the cells into mesodermal lineage adipocytes and endodermal lineage 
pancreatic cells. Our result might indicate a possible role of these cells in the expansion of 
cancer and aggressive spread, and even metastasis, with regards to their potency. As shown in 
Figure 4.6, from seven cells populations of neoplastic and distal tissues, one cell population 
showed a clear differentiation into adipocytes. The cells showed drastic up-regulation of 
PPARG mRNA, a master regulator of adipocytes differentiation, and accumulation of lipid 
vacuoles in cells cytoplasm. This finding could be an indication that stem cells from cirrhotic 
distal tissue of liver cancer tissue might still be multipotent. This sample is obtained from a 
liver cancer with a moderate level of differentiation. We assume that this tissue is most 
‘normal’ compared to the others tissues which allow cells-directed differentiation. 
 As far as the pancreatic differentiation is involved, we observed an induction of 
somatostatin and/or gastric inhibitory protein (GIP) a member of glucagon, marker for δ cell 
and α cell, respectively (Figure 4.7).  The islets of Langerhans are small organs located in the 
pancreas that are crucial for glucose homeostasis. Islets typically consist of four types of 
secretory endocrine cells, namely, the insulin-containing β cells, the glucagon-containing α 
cells, the somatostatin-containing δ cells, and the pancreatic polypeptide producing (PP) cells 
(Cabrera et al. 2006).   
In CC samples, the SST gene is expressed even in basal condition. A previous report 
showed that biliary epithelium is similar to the gastric or intestinal epithelia and many biliary 
tract carcinomas showed neuroendocrine differentiation (Marzioni, Fava, and Benedetti 
2006). Interestingly, sample which can be differentiated into adipocytes also have higher up-
regulations of SST and GIP after pancreatic induction. However, the expression of insulin, 
marker for β cells of pancreatic islets, is either absent or very low detected, at least at the 
mRNA level.  
However, the only evidence that proves a cell populations as a CSCs population is  by in 
vivo model. Our pilot in vivo study in nude mice showed that CD90 from cells with 
concentration up to 500,000 with at least 75% positivity and 95% viability were not able to 
induce tumor nodule in nude mice 4 months after injection (Table 4.3). Cells CSF01N and 
CSF09P were selected for this pilot study for their faster growth capacity compared the other 
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cells. These samples are originated from poor differentiated CC and HCC with cirrhosis. 
Previously it has reported that CD90 cells from primary tumors could promote tumor growth 
when they were injected orthotophically into the liver of the SCID/Beige mice (Yang et al. 
2008a).  In our model, we use nude mice FOXN1 (nu/nu) which is less immunodepressant 
than SCID/beige mice. Nude mouse with spontaneous or targeted deletion in the FOXN1 gene 
cannot generate mature T lymphocytes. In addition to lack of T lymphocytes, SCID/beige 
mouse cannot produce B lymphocytes and natural killer cells. Another additional point to be 
considered is that we injected the cells subcutaneously instead of ortothopically in the liver to 
check whether these cells are able to induce tumor in non-hepatic environment related with 
their metastasis potential.  
Yang et al. reported that CD90 cells from PLC and MHCC97L cell lines (moderate to high 
metastatic potential) were successfully promoted tumor in nude mice when they were injected 
subcutaneously. However, in our JHH-6 cell line which is very aggressive and 
undifferentiated, a mouse injected with 1 million JHH-6 CD90+ cells died 10 days after 
injection, whether mouse with JHH-6 CD90- survived. However, in our pilot study we used 
only one mouse for positive and negative control, and the death of positive mouse might be or 
might be not related to injected cells. As mentioned previously both JHH-6 CD90+ and 
CD90- are also positive for mRNA markers CD29, CD105, and CD166, just as in our primary 
cells culture. It seems that tumorigenic capacity of CD90 cells is really dependent to the 
aggresiveness of the cells, but further studies are clearly necessary.  
In summary, the absence of tumor 4 months after initiation may be caused by several 
reasons: 
1.  The isolated cells obtained from those two samples had limited capacity to induce a 
tumorigenesis. Their capacity might be related with aggressiveness of cancer and 
degree of differentiation, but more importantly because of the nature of the cells 
itself. 
2. Longer duration or higher cells concentration is needed to induce tumorigenesis. 
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3. More immunodepressant mice models are needed, for example: NOD/SCID mice or 
SCID/Beige mice.  
4. Several populations with shared CD90+CD44+ phenotypes in liver cancer. These 
different cells populations may act differently as CSCs or SCs in cancers. 
Interesting result obtained from cell line JHH-6 showed a particular behavior. JHH-6 is a 
very aggressive HCC cell line with undifferentiated morphology. In basal level, these cells 
express CD90 mRNA with quantity less than 1% checked by FACS. After magnetic cell sorting 
and validation of the cells purity, we followed up the changes in cells phenotype during 
subcultures. Both fractions concurrently expressed CD44 protein. Sorted cells showed that 
CD90+ cells can generate two clearly distinct populations of CD90+ and CD90- cells, but 
CD90- cells could harbor only CD90- (Figure 4.10).  We continued to subculture the cells 
until passage 21st after sorting until the CD90+ cells reached composition of positive and 
negative fraction for about 20% and 80%, respectively. In the other hand, until passage 21st, 
CD90- cells can be only 100% CD90- cells. This capacity of cells differentiation was also had 
been reported in ABCG2+ cells of HCC cell lines Huh-7 and PLC  (Zen et al. 2007) in which 
ABCG2+ fraction generate ABCG2+ and ABCG2-, and on the other hand ABCG2- could only 
generate ABCG2- cells. In contrast of CD133, sorted CD133+ and CD133- from Huh-7 and 
HuCCT1 cells similarly produced CD133+ and CD133- cells during subculture (Yoshikawa et 
al. 2009). 
This data shows that CD90+ cells might be at a the higher  hierarchy level than CD90- 
cells in liver cancer and might be one of responsible cell types in generating cancer 
heterogeneity. However, we should consider the regulation of CD90 expression. Marker Stro-
1 had been reported to decrease its expression during cells expansion (Gronthos et al. 2003). 
Regarding cells morphology, it has been reported that in murine pulmonary, CD90- 
fibroblasts had a more polygonal morphology than the more spindle-shaped CD90+ (Phipps 
et al. 1989). Although these differences had been credited to cells signaling activity, we have 
not seen any morphological differences in our JHH6 CD90+ and CD90- cells, checked by 
FACS and microscopy. 
  Chapter 7 – General Discussion 
 
111 
 
7.2. Tumor initiating and/or supporting cells?  
 
Recent studies and further information in cancer cell biology open a new discussion of 
these cells populations. As mentioned in General Introduction, interaction and cross talk 
between tumor cells and their microenvironment is crucial for cancer cells maintenance and 
expansion. Further assays will be needed to study these isolated cells populations, whether 
they are associated with the cancer associated fibroblasts (CAFs).  
Cancer-associated fibroblasts (CAFs) or cancer stromal cells are the most important cell 
type in the stroma. As described in General Introduction, tumor stroma is essential to support 
the tumor and the components of the stroma are vital for cancer initiation, growth and 
progression. The CAFs cells, the most important cells in the stroma, are important in the 
modulation of biological activities of the cancer, immunity, and expansion.  
The presence of the MSCs have been thought to meet the requirements of the CAFs. In 
addition to their similar spindle-shape morphology, MSCs and tissues fibroblasts are 
considered to be dynamic cells from at least the same lineage. They might also share the 
capacity of de- and re-differentiation that allow an overlapping biological impact (Lindner et 
al. 2010). In skin, the MSCs share common surface antigens and exhibit common functions 
with dermal fibroblasts (Haniffa et al. 2007). Because of the existence of MSCs in many types 
of normal and cancer tissues, trans-differentiation capacity of these cells is thought to be the 
n key characteristic to reside in the tissue host. The immunosuppresive properties of these 
cells are inferred to be a specialized function associated to their multipotency.  
The migration of MSCs from bone marrow to tumor in experimental sets has been 
demonstrated in several cancers such as breast, ovary and colon cancers (Dwyer et al. 
2007;Coffelt et al. 2009;Shinagawa et al. 2010). A review of breast cancer described that the 
MSCs from bone marrow or other tissues responds to numerous attractant signals including 
TGF-β, VEGF, and IL-6 from the tumor. Then in the tumor, MSCs joined the tumor stroma 
and produced bioactive molecules. The interaction of MSCs and tumor cells promoted tumor 
growth and metastasis (El-Haibi and Karnoub 2010). The mixture of human bone marrow-
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derived MSCs and weakly metastatic breast cancer cells caused the cancer cells increase 
metastatic potency in xenograft models. The cancer cells stimulate chemokine CCL5 from the 
MSCs which facilitate metastasis spread by a mutual interaction between stromal cells and 
cancer cells (Karnoub et al. 2007). In addition, a MSCs-CSCs niche in breast cancer has been 
studied. Both CSCs and MSCs are organized in a cellular hierarchy in which ALDH expressing 
mesenchymal cells regulate CSCs through cytokine networks (Liu et al. 2011).  
This new information opens further questions whether all cells isolated, or partially MSCs 
cells, are associated with CAFs in HCC. As described previously, the isolated cells population 
from the PLCs expressed several MSCs markers. They might be still multipotent to 
differentiate into other cell types, shown by expression of somatostatin after induction. 
Plasticity is one important requirement to act as the CAFs.  
In 2009, Mazzocca demonstrated a tumor-stromal interaction between CAFs and HCC 
cells. CAFs were essential for tumor growth and metastatis and mutually, tumor cells 
stimulated proliferation of the CAFs. HCC invasive cells produce high levels of connective 
TGF (CTGF) and generate tumors with high stromal component in vivo. The TGF-β inhibitor 
LY2109761 inhibited CTGF and consequently diminished tumor growth by inhibiting the 
proliferation of CAFs. In addition, by TGF-β1 stimulation, non-invasive HCC cells form tumor 
with high stromal content and CTGF expression, and again is inhibited with LY2109761 
(Fransvea et al. 2009;Mazzocca et al. 2010).  
Theoretically, cells with MSCs phenotypes may act as both tumor initiating and 
supporting cells in liver cancer. Their trans-differentiation and migration potency may allow 
them to be exist in the liver and replenish many type of cells. In regards to the CSCs theory, if 
mutations occur in this cell population, they could initiate and promote cancer and 
differentiate into cancer mass. On the other hand, by secreting soluble factors and creating 
supportive microenvironment on several difference stages, the MSCs may also responsible to 
maintain the expansion of the cancer.  
However, the real question is how tumorigenic cancerous our isolated cells can be in the 
development of liver cancer. One limitation in this study that we did not perform a single 
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clone culture, therefore, the isolated cells conducted for plasticity and in vivo studies could be 
resulted from several different cells which could be derived from several cells populations 
which share similar phenotypes CD90 and CD44. Another hypothesis that could be taken is 
whether there is a small subpopulation of CSCs in the isolated cells or in MSCs population in 
the liver cancer.  
Based on our preliminary data in nude mice after 4 months, we thought that the activity 
of these cells to initiate cancer and act as the real CSCs must be supported by a friendly 
environment that favors cancer development. As a preliminary data, when we checked for α-
SMA mRNA, all cells isolated from PLCs showed higher expression of this gene compared to 
an established cell line with similar phenotype in standard culture medium. This observation 
may indicate an activation of fibroblasts with CAFs characteristics in primary tumor. 
Interestingly, even though variations of α-SMA were observed, in many samples, this gene is 
more expressed in cells populations isolated from PLCs than one population from non-
tumoral tissues (data nor shown). The HLSCs from normal liver with similar phenotype with 
our cells population did not express α-SMA (Herrera et al. 2006).  We assumed that there 
must be an activation of these cells in a supportive microenvironment of primary cancers. 
However, this argument must be proven with further studies. 
In this study, we assumed that presence of both CSCs and MSCs in the liver cancers have 
several important concerns: 1) MSCs, CSCs, and activated-resident-fibroblasts in cancer share 
common markers and overlapping function; 2) the MSCs could be recruited and migrated 
from bone marrow or other tissues to give support for tumorigenesis; and 3) it is widely 
known that MSCs are also found in normal liver tissues. If mutations occurs and change the 
nature of the cells, they might promote tumor growth and at the same time alter their 
plasticity which may act as supportive components that favor microenvironment of the 
tumor. This last argument is a model of CSCs theory and thus will be correlated with small 
percentage of the CSCs in the whole liver cells population.  
The evidence of mutated MSCs as CSCs was demonstrated in sarcoma, a non-epithelial 
non-hematopoietic cancer derived from embryonic mesoderm. MSCs were found to rapid 
proliferate and differentiate at locations where especially in children sarcomas are often 
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found. This capacity might increase the occurrence of transformations into CSCs   (Mohseny 
and Hogendoorn 2011;Honoki 2010).  
Taken this information all together, further studies, especially in vivo assay, to analyze 
our isolated cells population will be very important. The combination of the clonogenic MSCs 
from PLC and non-cancerous MSCs from normal tissues with differentiated HCC cells will 
give more comprehensive data of tumor-stromal interaction. 
 
7.3. Stem cells marker gene in liver tissues 
 
Even though global gene expression analysis is a potent tool to distinguish different 
subtypes and to predict prognostic value of HCC patients based on molecular markers, single 
CSCs marker had been attempted to study its association with clinical significance. Many 
reports also emphasize the importance of the expression of these markers with cells origin of 
the cancer and potential future therapy. 
In the second task of my thesis we focus our attention to the study of several stem cells 
markers which are commonly identified in liver cancer. We decided to analyze surface 
markers CD90 and CD133, epithelial molecule EpCAM, embryonic pluripotency factor OCT4, 
and more-committed hepatic progenitor markers CK19 together with CK7. We used several 
groups of liver disease: HCC, HB, BA, and normal tissues. Several samples of CC were used as 
control for cytokeratins expression. In general, many studies reported their expression in 
protein level, but we perform the study from a different approach as the mRNA level of 
several hepatic malignancies simultaneously. This approach provided us information on: 1. 
the transcription stage of these genes and 2. direct comparison within groups and among 
groups because we used similar individual samples and RNA extract from each groups.  
For quantitative real time PCR data, we used three reference genes 18s-rRNA, β-actin, 
and GAPDH to normalize the ABCG2 target gene expression. To recheck the result, the use of 
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recommended single reference gene 18S-rRNA separately for normalization gave similar 
trends in the result (Bustin et al. 2002). All the figures and data in this study represented 
normalization to three reference genes. 
As shown in Figure 5.1 to Figure 5.5, we found that all the genes expressed variably in 
human liver tissues. However, generally, in normal liver tissues, their variations are more 
limited compared to diseased liver. This observation could be noticed based on mRNA 
relative expression compared to a normal control normal sample and also on the Ct 
distribution in the target gene (Table 5.2 and Table 5.3). Interestingly, the CD90 and EpCAM 
are expressed significantly higher in liver cancers than in normal tissue (p<0.05). 
Furthermore, these genes are expressed distinctly among malignant livers.  
CD90 is a promiscuous molecule expressed in several cell types in the liver, including 
fibroblast, resident hepatic stem cells, and bone marrow derived cells. When gene study using 
total RNA extract of tissues specimens is performed, we should be aware of the origin of this 
expression. From our result, we observed that CD90 mRNA is expressed in all tissues samples 
although more homogenously in normal than that of diseased tissues. Its expression in HCC, 
HB, and BA are significantly higher than normal tissues (p<0.05 for HB and BA, p<0.01 for 
HCC). The overall distribution of CD90 mRNA in hepatic malignancies has a clear 
distinguished pattern (Figure 5.1). Based on this result, we assumed that the expression of 
CD90 in normal liver is relatively stable compared to diseased tissues, and in particularly to 
cancerous tissues. 
The mRNA data from this study is concordant with a recent data demonstrating protein 
expression of CD90 in HCC with and without bile duct tumor thrombi (BDTT). CD90 protein 
was highly expressed in poorly differentiated tumors than in moderately or well differentiated 
tumors (p<0.05) (Yu et al. 2011). This data is also in agreement with a recent mRNA data that 
CD90 is more expressed in tumoral tissues than non-adjacent non-tumor tissues (Lu et al. 
2011).  
 As mentioned previously, a higher expression of CD90 in tissues samples are also found 
in our isolated cells. In contrast, Linggala et al. reported that not all HCC tissues expressed 
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CD90 protein (Lingala et al. 2010). We assumed that due to variations in mRNA level, found 
to be high or low expressed, the protein expression might be not detected with low protein 
expression.  
The general distribution of EpCAM mRNA expression in liver malignancies is found to be 
like the CD90. It is expressed in all tissues, even though its expressions are more variable. 
The EpCAM mRNA expression in CC is significantly higher than normal tissues, reached 
more than 1000 folds compared to a control (data not shown). This result is concordant with 
previous observation that EpCAM expression is found high in CC than in HCC (de Boer et al. 
1999). The EpCAM expression in HCC, HB, and BA is significantly higher than normal tissues 
(p<0.05). Its expression in these 3 malignancies is also more variable than in normal liver 
(Figure 5.2).  
Both EpCAM and CD90 are expressed in early hepatic stem cells, even though the origin 
of the hepatic stem cells itself is still unclear. Regarding this, we can assume that in liver 
cancer, there is a fast proliferation of different cells populations with CD90 and EpCAM 
phenotype, most probably activation of early progenitor cells. This over-expression might be 
due to so-called reaction of stem cells or fibroblast-like cells, migration of MSCs in response 
to hepatic injury, or circulating stem cells (both hematopoietic and mesencymal) in liver 
blood vessels. However, for CD90, it has been reported in rat liver fibrosis model using 2-
acetylaminfluorene/partial hepatoctomy, CD90 is expressed not in oval cells during cells 
proliferation, but in myofibroblasts or activated hepatic stellate cells (Dezso et al. 2007).  
Song and colleagues proposed a significance of CD133 expression to HCC prognostic 
(Song et al. 2008). In contrast, a recent article suggested that evaluation of CD133+ or 
CD133+/CD44+ cells in HCC and in colocteral carcinoma metastasis was not sufficient to 
serve as single prognostic parameter (Salnikov et al. 2009). We showed that in our samples 
not all of HCC samples expressed CD133 mRNA, and possibly also protein (Subchapter 5.4). 
This observation raises questions whether CD133 is a good marker for prediction of clinical 
significance. Our result is concordant with recent article from Lingala et al. that cancer 
tissues with CD133 expression was found in only two third of HCC specimens (Lingala et al. 
2010).  
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An intriguing result of CD133 and OCT4 mRNA expression is found in cirrhotic sample of 
BA as shown in Figure 5.3 and Figure 5.4. Even though a linear relationship between 
expression of CD133 and OCT4 could not be demonstrated due to small sample size of BA, we 
notice that both of these markers were highly expressed in BA samples. Previous study in 
rectal cancer with chemoradiotherapy (CRT) showed there were significant linear correlations 
among CD133, OCT4, and SOX2 which may be associated with tumor relapse and metastatic 
growth after CRT (Saigusa et al. 2009).  
Histologically, all BA tissues examined were cirrhotic. Based on the literature review, 
several recent articles reported a subpopulation in stellate cells expressed high CD133 and 
OCT4. As described in the General Introduction, subpopulation of CD133 cells was identified  
in hepatic stellate cells (Kordes et al. 2007). Moreover, stellate cells display a differentiation 
potential as investigated in vitro and in vivo. It indicates that stellate cells are 
undifferentiated cells, which might play an important role in liver regeneration (Kordes, 
Sawitza, and Haussinger 2009). Stellate cells are activated and responsible to develop liver 
fibrosis and progress to cirrhosis.  
Pattern of CD133 and OCT4 in clinical tissues was simultaneously found in our isolated 
cells population from primary cancers (please refer to previous subchapter 7.1). Beside the 
presence of MSCs, we noticed that only in HCC with Hepatitis C Virus (HCV) cells, there are 
higher mRNA expressions of CD133 together with OCT4 compared to viral-free HCC.  
Moreover,  HCC tissues with HCV infection also express high expression of CD133. It is 
widely known that HCV infection lead to liver cirrhosis. An interesting study reported the 
presence of CD133/Nanog-postive cells in liver tumors of alcohol fed in NS5 transgenic 
mouse. This synergism between HCV, alcohol, and stem cell marker Nanog is mediated by 
Toll-like receptor 4 (Machida et al. 2009). Further studies in the association between HCV, 
cirrhosis/HCC and hematopoietic cells interaction will be intriguing.  
Tai et al. showed that using liver stem cells undergoing differentiation to mature 
hepatocytes, the expression of OCT4 diminished (Tai et al. 2005). In this study we still 
observe OCT4 mRNA in normal liver tissues because, however, normal tissues still contains 
normal stem/progenitor cells even in small number. However, unfortunately, the mRNA data 
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of OCT4 will be not sufficient. The observation of OCT4, especially in normal adult tissues, is 
controversial, therefore must be proven by at least protein assay. This study should be 
considered as a starting point in mRNA data. Further analysis on different genes exons and 
variants must be followed.  
In conjunction with gene expression studies on proposed CSCs marker above, we decided 
also to check the expression of CK19 and CK7. We considered these genes even if CK19 and 
CK7 act as markers for fully mature cholangiocytes. CK19 together with CK14 antigen shares 
same epitope with OV-6 target antigen, an antibody to recognize hepatic progenitor cells 
(Bisgaard et al. 1993).  For this reason, observation on the proliferation of more committed 
hepatic resident cells in tissues samples might be carried out. 
As shown in Figure 5.5, we found that CK7 is distributed variably and there is no 
significant difference among tissues samples, at least in the mRNA level. The CK19 is also 
wide expressed, but is found to be higher in liver cancers and significantly highest in BA 
compared to normal tissues. Data in HCC is concordant with a recent report showing that 
CK19 antigen was found to be positive in HCC and cirrhotic tissues in which its expression in 
HCC to be higher. Moreover, this marker was also positive in non-tumor liver tissues (Oliva et 
al. 2010). 
High expression of CK19 and CK7 in BA is thought to be an effect of bile duct cells 
proliferation. In BA samples, CK19 expression was found to be highest among other 
malignancies. This data is also in agreement with previous reported data that antibodies CK19 
and OV-6 stained ductular proliferative cells extensively, and not in hepatocytes, in extra 
hepatic BA patients, although OV-6 staining was more selective in the number and type of 
cells that were immunopositive (Crosby et al. 1998). It showed higher proliferation of CK19 
cells in the response of biliary disturbance compared with liver cancer. This proliferation 
might be explained by proliferation of bipotent hepatic progenitor cells and hepatoblasts, 
hepatic metaplasia, and abnormal proliferation of intrahepatic bile duct cells. Tan et al. 
reported that extra hepatic BA may be caused by a failure in the remodeling process in fetal 
stage development. Furthermore, proliferating ductules in this disease is similar with first 
trimester ductal plate-derived primitive bile ducts (Tan et al. 1994). 
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We thought that hepatoblastoma (HB) with the absence of essential other liver diseases, 
aging, viral infections, and abundance drugs exposure, might be the best candidate to study 
CSCs theory. In our HB samples, one HB neoplastic nodule showed highest expression of all 
CSCs marker CD133, CD90, EpCAM, CK7, and CK19. Cairo et al. divided molecular signature 
of HB into two groups: well-differentiated HB which is less aggressive with more CSCs 
markers (C1) and poor-differentiated HB which is more aggressive with fewer CSCs gene 
expression (C2). We predicted that this sample belongs to the C1 group (Cairo et al. 2008). 
Two HB neoplastic nodules showed a mutual high EpCAM and CK19 expression and 
considerably low β-catenin (CTNNB1) expression. Interestingly, we noticed that all highest 
expressions EpCAM and some of CD90 are found in HB patients and young HCC patients 
(data not shown).  
As mentioned previously, the differential expression of the tumoral compared to non 
tumoral tissue (distal) of liver cancers might be a better approach to study the gene up-
regulations related with progression of the diseases. We studied the mRNA expressions of 
several SCs markers described above in paired samples of the same patient. As we assumed 
that the basal expression of these genes varies in every patient, the comparison in each 
individual will give a more meaningful and relevant information on the possible regulation. 
As shown in Figure 5.6 and 5.7, in agreement with previous result, the most interesting 
pattern is observed for CD90 and EpCAM. Almost all samples showed drastic up-regulations 
in tumoral compared to distal tissues. In CC sample, tumoral samples showed differential 
expression >1.00 of all SCs markers gene under study. 
Taken data all together from CD90, EpCAM, and CK19, markers for several early liver 
stem cells and progenitor cells, we assume that liver cancers might be associated with 
proliferation of hepatic stem cells. However, in regards to liver cancers, proliferation of more-
primitive stem cells may be more than proliferation of more-committed progenitor cells.  
Collectively, gene expression data of several stem cells markers in liver malignancies 
support the CSCs theory regardless the origin of the cells. It might be related also with poor 
prognostic of the patients. As mentioned before, beside various risk factors and individual 
intrinsic variations, proliferation of various cells might happen in the response of liver injury 
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or as the cause of the hepatocarcinogenesis itself. Despite of the ample promising data in this 
study for CSCs in liver cancer, the use of CSCs mRNA marker to screen tissues in liver 
diseases might still be limited by several factors: 
1. The mRNA expressions of these markers were also identified in inflamed liver, 
normal liver, and nearly normal liver, even though more limited and homogenous. A 
recent article using immunohistochemistry reported that the expressions of 
individual or a combination of CSCs marker CD133, CD44, and ALDH in HCC was 
not a unique phenomenon. They were expressed randomly in HCC in spite of the 
presence of viral infection, advance fibrosis, and cirrhosis (Lingala et al. 2010). 
2. The origin of the cells that are associated with mRNA expression should be identified. 
Hepatic stem cells, hepatic fibroblasts, myofibroblasts, and MSCs share a common 
marker CD90. Moreover, CD133 expression might be obtained from circulating 
hemotopoietic cells and proliferating subpopulation of hepatic stellate cells in liver 
injury.  
3. Post-transcriptional and post-translational regulation and modification. In mouse 
cerebrum, CD90 mRNA expression was rapidly followed by protein expression, 
whereas a delay of several days occurred between CD90 mRNA and protein in mouse 
Purkinje cells  (Xue and Morris 1992) 
4. The possible influence of circulating cells in liver blood vessel, transit cells, and 
migrated cells. The presence of circulating CSCs CD90 in peripheral blood has been 
demonstrated (Yang et al. 2008b). 
5. The expression patterns of various stem cell markers in tumor sites may be different 
among individuals, possibly also due to the heterogeneity of activated signaling 
pathways in normal stem/progenitor cells where the CSCs may originate. Therefore, 
it would be useful to comprehensively investigate the expression patterns of stem cell 
markers to characterize the population of CSC that may correlate with the activation 
of their distinct molecular pathways (Yamashita et al. 2008). 
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However, it is important to consider that both in both malignant and normal tissues, the 
existence of stem cells population shares similar phenotype markers. Hence, it is essential to 
study the disparity of these normal and tumorigenic stem cells.  
 
7.4. ABCG2 as marker for hepatic CSCs 
 
In this thesis, chapter of ABCG2 expression is separated from other CSCs markers. Even 
though ABCG2 has been associated with CSCs marker, we considered it is not the most 
desirable marker for CSCs by several reasons. First, its determination is based on the protein 
functional activity. Second, ABCG2 is expressed in wide variety of cells including in mature 
differentiated cells. And third, the method of isolation of side population (SP) cells by flow 
cytometry really depends on individual techniques, dyes, and experimental factors. We 
thought that expression of ABCG2 is not real CSCs per se, but more likely supportive dynamic 
for the cancer in response to drug therapy.  
Based on our results, the ABCG2 mRNA expression in liver tissues is observed to be 
highly variable. The variations of ABCG2 intra- and inter-groups observed in this study had 
also been reported in acute leukemia (Ross et al. 2000), breast cancer (Burger et al. 2003) 
and lung cancer (Kawabata et al. 2003). We hypothesized that these variations were linked to 
individual variations such as age and severity of the disease, and drug therapy factors such as 
type of the drugs and duration of the treatments. Furthermore, regarding the main function 
of the liver, expression of ABCG2 is also related with individual lifestyle such as alcohol intake 
and chemical consumption. We noticed that ABCG2 expressions in normal liver tissues are 
related with age, to be low in children and high in adult (Figure 6.1). In liver cancers, ABCG2 
mRNA expression is significantly higher than normal and BA livers (Figure 6.2). It is an 
interesting observation that normal liver, especially of children liver, and BA tissues are ones 
with minimal cytotoxic drugs exposure. In contrast, our cancer tissues were obtained from 
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liver transplantation and liver resection patients who received treatments, and consequently 
increase the defense cells reaction. 
High variation in ABCG2 expressions demonstrated that its expression might be 
dependent on the tissues types, even in the same organ of an individual. Tumor proliferation 
and loss of cell differentiation may also induce ABCG2 up-regulations. Furthermore, a recent 
paper showed that knock-down of ABCG2 inhibited breast cancer and lung cancer cells 
proliferation, suggesting the role of ABCG2 in maintenance of the cancer cells (Chen et al. 
2010). Our finding data is difference with one reported in colon and cervical cancer in which 
ABCG2 protein was observed to be down-regulated (Gupta et al. 2006). However our data 
was in good agreement with previous finding demonstrated that ABCG2 protein and mRNA 
was higher in HCC compared to control group (Sun et al. 2010), was up-regulated following 
chemotherapy in HB patients (Vander et al. 2008), and was also reported to be induced in 
human livers after acetaminophen overdose and primary biliary cirrhosis (Barnes et al. 
2007). 
The lack of naïve tissues before treatment in our tissues samples is an unavoidable 
limitation in this study. As mentioned before, basal ABCG2 expression in each individual may 
vary and we cannot compare the data before and after treatment. To support data in vivo, we 
used several hepatic cell lines with different degree of morphological differentiation (IHH, 
HuH-7, HepG2, and JHH-6) as shown in Figure 3.1. Highest basal ABCG2 expression was 
found in JHH-6, the poorest differentiated HCC cell line (Figure 6.3). Interestingly, when we 
exposed these cells with doxorubicin, highest up-regulation was noticed in cells with low 
basal ABCG2 expression, which are immortalized hepatocytes and differentiated HCC cells 
(Figure 6.5). We hypothesize that in these cells with low ABCG2 expression, in the presence of 
drugs, ABCG2 is highly induced to pump out the drugs and to overcome the toxicity of the 
compounds. The data in HepG2 cells supports a previous report from Li et al. in which 
ABCG2 mRNA was also up-regulated in doxorubicin-resistant HepG2 (Li et al. 2007). 
However in our data, the increase of ABCG2 in HepG2 is less (2-folds compared the reported 
9-folds). It might be due to the different exposure time and dosing of doxorubicin on the cells. 
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As mentioned, the introduction of ABCG2 as CSCs is mainly due to its function in the 
cells protective mechanism. So we performed functional analysis of this transporter using 
Hoechst 33342 efflux assay in HCC cell lines. Immortalized hepatocyte IHH was excluded 
because of very low basal ABCG2 expression and no protein band was detected. We observed 
that the increase concentration of Hoechst 33342 raised cells efflux capacity in all cells, 
detected by spectro-fluorescence instrument (Table 6.1). Hoechst 33342 is a substrate for 
ABCB1/P-GP and ABCG2, thus, using this technique we could not distinguish which 
transporter has bigger role for Hoechst efflux.  
To see only the ABCG2 activity, we subtracted the fluorescence of internal dye 
accumulations with and without verapamil. Verapamil is potent P-GP inhibitor but weak 
ABCG2 inhibitor. Among all three cell lines, the smallest difference is observed in JHH-6 
indicating that ABCG2 efflux capacity was dominant in JHH-6 compared to HepG2 and HuH-
7 (Figure 6.6). It shows that the high expression of ABCG2 transcription level also has an 
active functional role in the cellular response to the potentially toxic compounds.  
Combining the data all together, we suppose that even though the ABCG2 is not an ideal 
marker for determining a CSCs population, there is an association of this transporter in the 
level of gene, protein, and functional activity with cells degree of differentiation. The 
relationship between cell differentiation and ABCG2 expression had been reported in studies 
performed in other cells.  A high level of functional ABCG2 was detected in undifferentiated 
human embryonic cells and decreased during cellular differentiation (Apati et al. 2008). In 
hematopoietic system, the ABCG2 expression is restricted to the most immature progenitor 
cells and down-regulated at the committed progenitor level (Scharenberg, Harkey, and 
Torok-Storb 2002).   
Nonetheless, drug resistance mechanism in cancer is a complex biological interaction that 
consisted of many transporters and activated signaling pathways. To fully understand this 
phenomenon, better information in the up-regulation of other transporters i.e. ABCB1, 
ABCC1, and ABCC3, as the most studied ABC transporters proteins in liver cancers, will be 
crucial. 
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More information of CSCs uniqueness and activation would be one of main keys in 
understanding initiation and development of cancer. Furthermore, to achieve a better 
strategy for a total elimination of HCC, several biological and clinical aspects should be 
considered for an effective CSCs-targeted therapy (Sukowati et al. 2010). The hepatic CSCs 
identifications and their functional significances, including multidrugs resistance behavior 
and aberrant signaling pathways should be considered. Together with CSCs markers, clinical 
aspects such as drug delivery system, single or combination therapy, drug dose and toxicity 
will support the potential of therapy. 
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8.1. Identification of stem cells population in PLCs 
 
We had identified the presence of cells populations with CD90+CD44+  phenotypes in 
human primary liver cancers Hepatocellular Carcinoma and Cholangiocarcinoma and non 
tumoral liver. These cells also express mesenchymal stem cells characteristic, identified based 
on morphology, cell surface antigens mRNA, and functional capacity. These cells populations 
from cancerous tissues have characteristics: 1. clonogenic capacity in standard culture 
condition and three dimensional matrices; 2. effectiveness for cells expansion in vitro; 3. 
trans-differentiation potentials that may allow them to promote and to support cancer 
growth; and 4. a probable player in cancer heterogeneity.  
Due to wide variations of liver cancers, the function of these cells populations may 
depend on many factors, such as severity of the disease, prognostic type, etiological factor, 
and exposure to the treatment. We thought that these cells may have capacity to play a role as 
tumor-initiating cells or tumor-promoting cells in liver cancer, however a more 
comprehensive xenograft in vivo assay will need to be further investigated. 
 
8.2. The distribution of stem cells phenotypic markers in liver 
cancer tissues 
 
Albeit an ideal global gene expression assay to study prognostic type of liver cancers, we 
presume that CSCs single marker might still be useful as support of the clinical significance of 
the cancers. From our data, we demonstrated that high expression of stem cells genes in 
disease tissues may suggest an active proliferation of CSCs in accordance with tumorigenesis, 
regardless the origin of CSCs. In more detail, our study showed that: 
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• In normal liver, the expressions of stem cells genes, especially CD90 and EpCAM, are 
more restricted than in diseased tissues.  
• High variability of CD90 (Thy-1), EpCAM, and CD133 (Prom-1) expression in hepatic 
malignancies.  
• The expression of CD90 and EpCAM is significantly higher in liver cancers than in 
normal liver. In paired tissues, differential expression between neoplastic nodules 
and distal tissues are also observed for these two genes. In addition, highest EpCAM 
expression is identified in HB and HCC samples from young patients with absence of 
viral infections. 
• In liver cancers, proliferation of more-primitive stem cells is higher than proliferation 
of more-committed progenitor cells. 
• High expressions of CD133 in biliary atresia and cirrhotic livers are observed 
compared to normal and liver cancer tissues. 
 
8.3. ABCG2: drug resistance and CSCs 
 
Regarding the expression of ABCG2 in regards to stem cells and side population study, we 
demonstrated that : 
• High variability of ABCG2 mRNA in normal and diseased liver. 
• An association of ABCG2 in the level of gene, protein, and functional activity with 
hepatic cells degree of differentiation, examined in vitro in hepatic cell line models.  
• A close relation of ABCG2 expression with chemoresistance to doxorubicin. 
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All the data shown in this study has supported the presence of stem cells in liver cancer. 
This summary contributes in the knowledge of hepatocarcinogenesis and cancerogenesis in 
general. However, more data in the characterizations of both normal and cancerous stem cells 
together with their functions in liver cancer tissues are important for better understanding 
their mechanisms in cancer initiation, maintenance, and treatment. 
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Supplemental data 1 
Characteristic of hepatic cell lines 
 
Cell 
Lines 
Characteristics Medium Passaging 
IHH Hepatic non tumoral 
cells 
DMEM/F12 1x medium with 15 mM 
Hepes buffer, L-glutamine, pyridoxine 
HCl; 1µM dexamethasone; 5 µg/mL 
insulin; 1% antibiotics; 10% FBS 
0.05% trypsin-
EDTA with 
centrifugation 
HepG2 Hepatocellular 
carcinoma 
DMEM-HG medium; 2 mM L-
glutamine; 1% antibiotics; 10% FBS 
0.05% trypsin-
EDTA with 
centrifugation 
HuH-7 Differentiated 
human hepatoma 
DMEM-HG medium; 2 mM L-
glutamine; 1% antibiotics; 10% FBS 
0.05% trypsin-
EDTA without 
centrifugation 
JHH-6 Undifferentiated 
Hepatocellular 
carcinoma 
Williams'E medium; 2 mM L-
glutamine; 1% antibiotics; 10% FBS 
0.05% trypsin-
EDTA without 
centrifugation 
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Supplemental data 2 
Body weight of xenograft mice post-inoculation 
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